

Quantifying the impact of interventions against *Plasmodium vivax* malaria: a model for country-specific use

C. Champagne^{1,2,*,**}, M. Gerhards^{1,2,*}, J. Lana³, A. Le Menach³ and E. Pothin^{1,2,3}

¹Swiss Tropical and Public Health Institute, Basel, Switzerland

²University of Basel, Basel, Switzerland

³Clinton Health Access Initiative, Boston, USA

*equal contribution

**Corresponding author: clara.champagne@swisstph.ch

February 8, 2023

Abstract

In order to evaluate the impact of various intervention strategies on *Plasmodium vivax* dynamics, we introduce a simple mathematical model that can be easily adapted to country-specific data. The model includes case management, vector control, mass drug administration and reactive case detection interventions and is implemented in both deterministic and stochastic frameworks. It is available as an R package to enable users to calibrate and simulate it with their own data. By simulating and comparing the impact of various intervention combinations on malaria risk and burden, this model can be a useful tool for strategic planning, implementation and resource mobilization.

Keywords

Plasmodium vivax model, Malaria model, *Plasmodium vivax* intervention

1 Introduction

Plasmodium vivax malaria is a parasitic infection responsible for about 4.9 million cases in 2021 [World Health Organization, 2022b]. While generally considered as less severe than *Plasmodium falciparum* malaria, *P. vivax* represents the majority of the remaining cases in many countries where elimination goals have been set for 2025 or 2030, including many countries in Asia (Bhutan, Nepal, Thailand, Republic of Korea, Democratic People's Republic of Korea), the Pacific (Vanuatu) and the Americas (Costa Rica, Ecuador, Guatemala, Honduras, Mexico, Panama, Suriname) [World Health Organization, 2022b, 2021]. Due to various distinguishing biological characteristics such as its capacity to remain dormant in the liver of infected individuals before its reactivation or its very early transmissibility potential, *P. vivax* is particularly difficult to eliminate. Therefore, reaching the elimination targets requires specific strategies that combine the various available interventions. These interventions include anti-malarial treatments, chemoprevention, case detection and vector control [World Health Organization et al., 2015a, Bassat et al., 2016] and are described in Table 1, highlighting their specific strengths and weaknesses.

Because of the advantages and challenges involved with each type of intervention, defining the most appropriate combination of interventions highly depends on context-specific factors, such as the level of transmission, ecological factors, the vulnerability to case importation or the characteristics of the health system [Cohen et al., 2017]. Therefore, the choice and adaptation of the malaria intervention strategy required to reach elimination targets needs to be tailored to local context. Mathematical modelling can be used to

Intervention and Mode of action	Advantages	Limitations
<p>Treatment/Case management:</p> <ul style="list-style-type: none"> • Clearance of blood-stage parasites responsible for the acute infection • Clearance of dormant liver-stage parasites (radical cure) with 8-aminoquinolines such as primaquine (PQ) and tafenoquine (TQ) 	<ul style="list-style-type: none"> • Reduces disease burden [Chu and White, 2021] • Reduces the parasite’s capacity for ongoing transmission by reducing the number of relapses and the number of infectious days [Chu and White, 2021] 	<ul style="list-style-type: none"> • 8-aminoquinolines have restricted eligibility criteria, long treatment scheme and potential adverse effects [Bassat et al., 2016, Chu and White, 2021, Thriemer et al., 2021] • Reaching high effective treatment coverage depends on various components, including physical accessibility to diagnostic and treatment, compliance of the health system or adherence to the treatment scheme [Galactionova et al., 2015, Emerson et al., 2022] • The effectiveness on transmission is limited given the high proportion of patients presenting to health facilities with gametocytes [Douglas et al., 2010] indicating they might already have participated in transmission before being treated.
<p>MDA: Mass drug administration or mass chemoprevention</p>	<ul style="list-style-type: none"> • A potential elimination accelerator permitting a rapid reduction of the parasite reservoir in the host population • Deployed in the past in various settings with various success rates [Poirot et al., 2013] 	<ul style="list-style-type: none"> • The evidence from randomized control trials points to a positive short term effect that is most likely not sustained in the longer term if elimination is not reached or if not complemented with additional interventions used in combination [Poirot et al., 2013, Shah et al., 2021]. • Logistical, safety and acceptability challenges, especially regarding the mass use of 8-aminoquinolines • Mass use of 8-aminoquinolines not recommended by the World Health Organization [World Health Organization et al., 2015a, Alonso, 2020, World Health Organization, 2022a]
<p>Reactive case detection: Typically, investigations are conducted in the vicinity of index cases so to enhance the likelihood of finding additional infections that would otherwise have escaped the health system</p>	<ul style="list-style-type: none"> • Reduces community transmission by identifying infected individuals that have yet to (and may not plan to) seek care • Part of the WHO strategic pillar to “transform malaria surveillance into a core intervention” [World Health Organization et al., 2015b] • Credited to contributing to the successful elimination strategies in China and El Salvador [Perera et al., 2020, Burton et al., 2018, Balakrishnan, 2021] 	<ul style="list-style-type: none"> • Challenges in the feasibility of this resource intensive activity which may take resources away from routine surveillance and diagnosis activities • Uncertainty in the conditions for its effectiveness and difficulty to monitor effectiveness [van Eijk et al., 2016, Perera et al., 2020, Hetzel and Chitnis, 2020]
<p>Vector control: Killing or repelling the <i>Anopheles</i> mosquitoes responsible for parasite transmissions, via interventions such as insecticide treated bednets (ITNs) or indoor residual spraying (IRS)</p>	<ul style="list-style-type: none"> • Complementary elimination tool to reduce the likelihood of transmission when cases are not treated promptly or correctly • Key component of the WHO recommended prevention strategies [World Health Organization et al., 2015a] • ITNs has been one of the most important drivers of the reductions in malaria burden in Africa in the beginning of the 21st century [Bhatt et al., 2015] 	<ul style="list-style-type: none"> • Many eliminations settings outside of Africa harbour mosquitoes species with different characteristics, such as early biting behaviours or different response to insecticides that reduce intervention effectiveness [Briët et al., 2019, Monroe et al., 2020]. • Logistical challenges to optimize deployment timing given the limited duration of effectiveness (especially IRS) • Acceptability and logistical challenges to reaching high coverage/usage of the interventions • Short term durability of the insecticides and nets, requiring frequent re-deployment of the interventions

Table 1: Description of the considered interventions

39 quantify the impact of the considered intervention strategies, identify the most impactful ones in each setting
40 [Owen et al., 2022]. Various *P. vivax* models have recently been developed (e.g. [White et al., 2018, Kim
41 et al., 2021, Tian et al., 2022]), but they are not always readily operationalized for being used routinely
42 at country level, either because they don’t include all the above-mentioned interventions, or because their
43 calibration to routine data is not straightforward to implement.

44

45 In order to address these shortcomings, a model was previously developed to represent *P. vivax* dynamics
46 at the local level in the presence of case management interventions, including a methodology to infer param-
47 eter values from available data based on the steady-state assumption [Champagne et al., 2022]. Nonetheless,
48 this model has some limitations that restrict its use in practice. Firstly, the model assumes that treatment

49 acts instantaneously, such that treated patients do not contribute to ongoing disease transmission [Douglas
 50 et al., 2010]. This assumption is not totally appropriate for *P. vivax*, for which treated patients might already
 51 have participated in transmission before the effect of their treatment. Secondly, it does not include other
 52 interventions such as reactive case detection (RCD) or mass drug administration (MDA), which are part
 53 of the malaria elimination toolbox for decision-makers. Finally, it is only implemented in the deterministic
 54 framework.

55
 56 The present work therefore extends the model by Champagne et al. [2022] by removing these limitations,
 57 thus increasing its potential applications for country-specific decision making. Such use-cases are illustrated
 58 in an example on three fictitious areas of varying endemicity. The extended model is publicly available as
 59 an R package (<https://swisstph.github.io/VivaxModelR/>) that can be applied to the users' own data.

60 2 Methods

61 2.1 Model of *P. vivax* dynamics with delayed treatment

62 *P. vivax* dynamics are represented by a compartmental model where the host population is divided between
 63 infectious and susceptible individuals who do or do not harbour liver stage parasites [White et al., 2016,
 64 Champagne et al., 2022]. In order to allow the possibility for treated individuals to infect mosquitoes before
 65 they effectively clear their parasites, the model by Champagne et al. [2022] is modified by adding two
 66 compartments representing treated individuals. Let T_L be the proportion of blood-stage infected population
 67 with liver-stage infection which received treatment, T_0 that of blood-stage infected population without
 68 liver-stage infection which received treatment, U_L that of blood-stage infected population with liver-stage
 69 infection but which did not received treatment and U_0 that of blood-stage infected population without liver-
 70 stage infection which did not receive treatment. We define $I := T_L + T_0 + U_L + U_0$ as the proportion of
 71 blood-stage infections. S_0 represents the proportion of fully susceptible individuals, and S_L represents the
 72 individuals who have cleared their blood stage parasites but still harbour liver stage parasites and hence have
 73 the possibility to experience a relapse. The model can be represented by the following system of equations:

$$\begin{aligned}
 \frac{dU_L}{dt} &= (1 - \alpha)(\lambda I + \delta)(S_0 + S_L) + (\lambda I + \delta)U_0 + (1 - \alpha)fS_L - \gamma_L U_L - rU_L \\
 \frac{dU_0}{dt} &= -(\lambda I + \delta)U_0 + \gamma_L U_L - rU_0 \\
 \frac{dT_L}{dt} &= \alpha(\lambda I + \delta)(S_0 + S_L) + \alpha fS_L - (\sigma + r + \gamma_L)T_L + (\lambda I + \delta)T_0 \\
 \frac{dT_0}{dt} &= \gamma_L T_L - \sigma T_0 - (\lambda I + \delta)T_0 - rT_0 \\
 \frac{dS_L}{dt} &= (1 - \beta)\sigma T_L - (\lambda I + \delta)S_L - fS_L - \gamma_L S_L + rU_L + rT_L \\
 \frac{dS_0}{dt} &= -(\lambda I + \delta)S_0 + \beta\sigma T_L + \sigma T_0 + \gamma_L S_L + rU_0 + rT_0
 \end{aligned}
 \tag{1}$$

74 All other parameter notations are indicated in Table 2 and a schematic representation of the model is
 75 presented in Figure 1. In this model, case management is thus represented via three parameters. The first
 76 parameter is the proportion of individuals receiving effective treatment (α), i.e. the proportion of individuals
 77 whose blood-stage parasites are effectively cleared due to treatment, if they don't recover naturally before.
 78 The second parameter (β) is the proportion of treated individuals who experience radical cure, i.e. the
 79 clearance of liver-stage parasites in addition to blood-stage parasites. The third parameter (σ) quantifies
 80 the time during which a treated individual can transmit the disease to mosquitoes (ignoring potential re-
 81 coveries that could happen during this interval, see Appendix A for more details). All three parameters can
 82 be informed by data on the health system, following the effective coverage framework [Galactionova et al.,
 83 2015]. A description of the rationale for choosing the formulation in equation (1) is presented in Appendix
 84 A in the context of perfect radical cure.

85

Notation	Description	Unit	Definition range
State variables			
U_L	Untreated individuals with liver and blood stage parasites	.	[0,1]
U_0	Untreated individuals with blood stage parasites only	.	[0,1]
S_L	Susceptible individuals with liver stage parasites	.	[0,1]
S_0	Fully susceptible individuals	.	[0,1]
T_L	Treated individuals with liver and blood stage parasites	.	[0,1]
T_0	Treated individuals with blood stage parasites only	.	[0,1]
Parameters			
λ	Transmission rate	time ⁻¹	≥ 0
r	Blood stage clearance rate	time ⁻¹	≥ 0
γ_L	Liver stage clearance rate	time ⁻¹	≥ 0
f	Relapse frequency	time ⁻¹	≥ 0
δ	Importation rate	time ⁻¹	≥ 0
α	Proportion of effective treatment	.	[0,1]
β	Proportion of radical cure	.	[0,1]
σ	Duration of infectivity for treated infections	time ⁻¹	≥ 0
ρ	Observation rate	.	[0,1]
RCD model			
l_{max}	Maximal number of index cases investigated	time ⁻¹	≥ 0
ν	Number of individuals investigated per index case	.	≥ 0
η	Proportion of effective care for infections detected by RCD	.	[0,1]
τ	Targeting ratio	.	≥ 0
MDA model			
c_{MDA}	MDA coverage	.	[0,1]
β_{MDA}	Proportion of radical cure for MDA	.	[0,1]
t_{MDA}	Starting date of MDA	time	≥ 0
p_{MDA}	Duration of MDA prophylaxis	time	≥ 0

Table 2: Description of state variables and model parameters.




Figure 1: Schematic representation of the model for *P. vivax* dynamics including delayed access to treatment.

86 The corresponding reproduction numbers in the presence of control interventions (R_c) and in the absence
 87 of control (R_0) are calculated using the next-generation matrix approach [van den Driessche and Watmough,
 88 2002] as follows:

$$R_c = \frac{\lambda(f + \gamma_L)(\gamma_L + r)(\gamma_L + r + \sigma)(r + \sigma(1 - \alpha))}{r(r + \sigma)(\gamma_L(f + \gamma_L + r)(\gamma_L + r + \sigma) + \alpha f \sigma[\beta(r + \gamma_L) - \gamma_L])} \quad (2)$$

89 and

$$R_0 = \frac{\lambda(f + \gamma_L)(\gamma_L + r)}{r\gamma_L(f + \gamma_L + r)} \quad (3)$$

90 As expected, the basic reproduction number R_0 in the absence of control is identical to the one in the model
 91 where the effect of delay in treatment access was neglected [Champagne et al., 2022], because in this hypo-
 92 theoretical context no individual receives any treatment. Similarly to Champagne et al. [2022], a polynomial
 93 relationship between the transmission rate λ and observable quantities can be calculated, as detailed in
 94 Appendix B. With this relationship, the model can easily be calibrated to reported incidence data.
 95

96 2.2 Including reactive case detection

97 Reactive case detection (RCD) can be included in the model based on the framework by Chitnis et al. [2019].
 98 With this approach, reactive case detection adds the possibility for non-treated cases to be detected and
 99 treated. The model relies on the assumption that cases are geographically clustered, such that the proba-
 100 bility of finding a case in the vicinity of a reported case is higher than the probability of finding a case in
 101 the general population. This increased likeliness of finding cases is modelled via the targeting ratio τ as in
 102 Chitnis et al. [2019], Das et al. [2022a]. The parameter ι indicates the number of index cases investigated per
 103 population per unit of time. The parameter ν indicates the number of secondary individuals investigated per
 104 index case. We add the parameter η to reflect the effective cure of RCD-detected individuals (including test
 105 sensitivity, compliance, adherence and drug efficacy). A schematic representation of the model is presented
 106 in Figure 2. Cases detected via RCD are assumed to receive effective radical cure with the same probability
 107 as other treated infections.
 108




Figure 2: Models including reactive case detection (RCD). A. Description of the assumptions for modelling RCD. B. Schematic representation of the model for *P. vivax* including delayed treatment and RCD (another model version in which cases detected via RCD need to be referred to a health facility for treatment and would experience a delay before being cured is presented in Appendix C.3).

109 The model with delay in treatment and reactive case detection, corresponding to Figure 2B, can be

110 represented by the following equations:

$$\begin{aligned}
 \frac{dU_L}{dt} &= (1 - \alpha)(\lambda I + \delta)(1 - I) + (1 - \alpha)fS_L + (\lambda I + \delta)U_0 - \gamma_L U_L - rU_L \\
 &\quad - \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_L \\
 \frac{dU_0}{dt} &= -(\lambda I + \delta)U_0 + \gamma_L U_L - rU_0 - \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_0 \\
 \frac{dT_L}{dt} &= \alpha(\lambda I + \delta)(1 - I) + \alpha fS_L + (\lambda I + \delta)T_0 - \gamma_L T_L - (r + \sigma)T_L \\
 \frac{dT_0}{dt} &= -(\lambda I + \delta)T_0 + \gamma_L T_L - (r + \sigma)T_0 \\
 \frac{dS_L}{dt} &= -(\lambda I + \delta + f)S_L + (1 - \beta)\sigma T_L - \gamma_L S_L + r(T_L + U_L) \\
 &\quad + (1 - \beta)\min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_L \\
 \frac{dS_0}{dt} &= -(\lambda I + \delta)S_0 + \beta\sigma T_L + \sigma T_0 + \gamma_L S_L + r(T_0 + U_0) \\
 &\quad + \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta(\beta U_L + U_0)
 \end{aligned}
 \tag{4}$$

111 The number of index cases investigated is written as $\iota = \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)$ and this
 112 formulation ensures that the number of index cases investigated is never higher than the number of cases
 113 detected.

114
 115 This model makes the assumption that cases detected by RCD are immediately effectively treated (tran-
 116 sition from U_L or U_0 to S_L or S_0). In some situations, the cases detected via RCD need to be referred to
 117 a health facility for treatment, hence they would experience a delay before being cured. Therefore, another
 118 version of the model in which infections detected via RCD enter the T_0 and T_L compartments instead of S_0
 119 and S_L was also developed and is presented in Appendix C.3 (called "with referral to health facility"). For
 120 completeness, the model with RCD but without delayed access to treatment is also presented in Appendix
 121 C.1.

122
 123 If $\nu\tau\eta = 0$, this model reduces to the model (1) without RCD. If τ is fixed (or at least bounded), all of
 124 the 'RCD terms' are of the order $O(I^2)$ for $I \rightarrow 0$, so the reproduction number R_C is equal to R_C in the
 125 model without any RCD. This means that RCD as modelled cannot interrupt sustained disease transmis-
 126 sion, nor can it overcome the effect of importation as soon as local prevalence is too low. So either with or
 127 without importation, RCD can only affect the magnitude of the endemic equilibrium and not the threshold
 128 behaviour between endemic and disease-free equilibrium. The intuition behind this phenomenon is that,
 129 as prevalence decreases, both the number of detected index cases and the number of cases found in each
 130 investigation decrease, such that the number of cases found by RCD is reduced. In practice, it could happen
 131 that this effect is compensated by another one, such as an increased clustering of cases around index cases
 132 represented with unbounded targeting ratio τ . For example, following Chitnis et al. [2019], τ could also be
 133 a time-varying quantity, which depends on the prevalence in the population and the number of secondary
 134 cases investigated, such that the targeting ratio increases as prevalence decreases and as ν decreases. A
 135 parametric function of the prevalence and ν fitted to data from Zambia is presented in Chitnis et al. [2019]
 136 and further used in Reiker et al. [2019] and could be substituted to the fixed values of τ .
 137 In all cases, extinction events may also occur when the endemic equilibrium is very low and the model is
 138 simulated in the stochastic framework (cf. below).

140 2.2.1 Relation between the transmission rate and observable quantities

141 The transmission rate λ can be calculated from observable quantities using the model's equilibrium with a
 142 similar methodology to Champagne et al. [2022], where a polynomial equation for λ is derived and solved
 143 numerically. The extension of this framework to the models with RCD is detailed in Appendix C. Nonethe-
 144 less, in order to use these polynomial equations in practice for calculating λ , additional calculations to derive

145 I^* , δ and ι^* from observable quantities are required. Let us introduce the following additional notations:

- 146 • at equilibrium, we note $\iota^* = \min(\iota_{max}, \rho(\lambda I^* + \delta)(1 - I^*) + \rho f S_L^*)$
- 147 • $h_1 = \rho(\lambda I^* + \delta)(1 - I^*) + \rho f S_L^*$ is the incidence of directly-detected infections
- 148 • $h_2 = \iota^* \nu \tau \eta (U_0^* + U_L^*)$ is the incidence of reactively-detected infections (assuming they are all perfectly
- 149 reported).
- 150 • $h = h_1 + h_2$ is the total incidence of detected cases
- 151 • p is the proportion of imported cases, such that $ph = \rho \delta (1 - I^*)$

152 With these notations, $\iota^* = \min(\iota_{max}, h_1)$, $(U_L^* + U_0^*) = \frac{1-\alpha}{\rho(r+\iota^*\nu\tau\eta)} h_1$ (using (28) in Appendix C),
 153 $\delta = \frac{ph}{\rho(1-I^*)}$ and I^* can be calculated using (32) in Appendix C. Therefore, one needs h_1 to back-calculate
 154 the value of λ .

155 Two situations can arise in practice:

- 157 1. only the total number of new cases h is known, regardless of whether cases are detected via direct
 158 detection or via reactive detection
- 159 2. the numbers of reactively detected and non-reactively detected cases are both known (h_1 and h_2).

160 2.2.2 Only the total number of new cases is known

161 In the first situation, we need to calculate the value of h_1 , and the value of h_2 will be $h_2 = h - h_1$.

162 We need to evaluate separately the two possibilities for ι .

163 If $\iota = \iota_{max}$, we have $(U_L^* + U_0^*) = \frac{(1-\alpha)h_1}{\rho(r+\iota_{max}\nu\tau\eta)}$. Hence $h = h_1 + \iota_{max}\nu\tau\eta(U_L^* + U_0^*) = h_1 + \frac{\iota_{max}\nu\tau\eta(1-\alpha)}{\rho(r+\iota_{max}\nu\tau\eta)} h_1$
 164 and

$$h_1 = \frac{h\rho(r + \iota_{max}\nu\tau\eta)}{\rho r + \iota_{max}\nu\tau\eta(1 - \alpha + \rho)}.$$

165 If $\iota = h_1$, we have $(U_L^* + U_0^*) = \frac{(1-\alpha)h_1}{\rho(r+h_1\nu\tau\eta)}$. Then, from $h = h_1 + h_1\nu\tau\eta(U_L^* + U_0^*) = h_1 + \frac{\nu\tau\eta(1-\alpha)}{\rho(r+h_1\nu\tau\eta)} h_1^2$,
 we get

$$h_1 = \frac{\rho\nu\tau\eta h - \rho r + \sqrt{(\rho\nu\tau\eta h - \rho r)^2 + 4\rho r h(1 - \alpha + \rho)\nu\tau\eta}}{2(1 - \alpha + \rho)\nu\tau\eta}.$$

166 Combining these two results, in the case of capped ι , we find

$$h_1 = \begin{cases} \frac{\rho\nu\tau\eta h - \rho r + \sqrt{(\rho\nu\tau\eta h - \rho r)^2 + 4\rho r h(1 - \alpha + \rho)\nu\tau\eta}}{2(1 - \alpha + \rho)\nu\tau\eta} & \text{if this is less than } \iota_{max} \\ \frac{h\rho(r + \iota_{max}\nu\tau\eta)}{\rho r + \iota_{max}\nu\tau\eta(1 - \alpha + \rho)} & \text{otherwise.} \end{cases} \quad (5)$$

167 2.2.3 The numbers of reactively detected and non-reactively detected cases are both known

168 If we know both h_1 and h_2 , we can calculate ι^* , I^* , δ and therefore λ directly. Additionally, we can combine
 169 this information to get an estimate of τ , which is otherwise difficult to find. We will consider only the cases
 170 where $h_2 > 0$ (otherwise, there is no effect of RCD and therefore no reason for using h_2 to calculate τ).

171 From equation (28) in Appendix C, we can infer

$$(U_L^* + U_0^*) = \frac{1}{r} \left[\frac{(1 - \alpha)h_1}{\rho} - h_2 \right], \quad (6)$$

172 which can be used in

$$\tau = \frac{h_2}{\iota^*\nu\eta(U_L^* + U_0^*)}. \quad (7)$$

173 2.3 Including Mass Drug Administration (MDA)

174 In order to model the deployment of an MDA campaign, the state variables representing the infectious
 175 population are depleted at the time of the MDA deployment depending on the MDA coverage. In order
 176 to model the time during which drug prophylaxis prevents targeted individuals from reinfections following
 177 MDA deployment, another model including two additional compartments is used. Finally, at the end of the
 178 prophylaxis time, the initial model without MDA can be simulated from the newly found initial condition.
 179 The overall framework is presented graphically in Figure 3.




Figure 3: Models including MDA (example of the model with delayed treatment).

180

181 We present here the equations of the model with delayed treatment and without RCD (1) as an example.
 182 Other model options with RCD or without delayed access to treatment follow the same approach and are
 183 detailed in Appendix D.

184

185 The simulation starts with the models defined by (1). The parameters of MDA, namely effective coverage
 186 c_{MDA} , starting time of prophylaxis t_{MDA} , duration of prophylaxis p_{MDA} and percentage of radical cure
 187 β_{MDA} , do not come into play in the ODEs. Instead, they affect the state variables of the system at a fixed
 188 point in time. At the time of MDA deployment t_{MDA} , the state variables of the system are modified as
 189 follows (using the notation $f(t_{MDA}^-)$ for the limit of $f(t)$ as t approaches t_{MDA}):

$$\begin{aligned}
 U_L(t_{MDA}) &= (1 - c_{MDA})U_L(t_{MDA}^-) \\
 U_0(t_{MDA}) &= (1 - c_{MDA})U_0(t_{MDA}^-) \\
 T_L(t_{MDA}) &= (1 - c_{MDA})T_L(t_{MDA}^-) \\
 T_0(t_{MDA}) &= (1 - c_{MDA})T_0(t_{MDA}^-) \\
 S_L(t_{MDA}) &= (1 - c_{MDA})S_L(t_{MDA}^-) \\
 S_0(t_{MDA}) &= (1 - c_{MDA})S_0(t_{MDA}^-) \\
 P_L(t_{MDA}) &= c_{MDA}(1 - \beta_{MDA}) (T_L(t_{MDA}^-) + U_L(t_{MDA}^-) + S_L(t_{MDA}^-)) \\
 P_0(t_{MDA}) &= c_{MDA}\beta_{MDA} (T_L(t_{MDA}^-) + U_L(t_{MDA}^-) + S_L(t_{MDA}^-)) + c_{MDA} (T_0(t_{MDA}^-) + U_0(t_{MDA}^-) + S_0(t_{MDA}^-)).
 \end{aligned} \tag{8}$$

190

191 To model the two effects of MDA (treatment and prophylaxis), we include two new compartments in the
 192 model. Let P_L and P_0 be the proportions of people that are effectively covered by MDA with and without
 liver-stage infection, respectively. We have the following set of ODEs to describe the dynamics of the system

193 during the prophylaxis period:

$$\begin{aligned}
 \frac{dU_L}{dt} &= (1 - \alpha)(\lambda I + \delta)(1 - I) + (1 - \alpha)fS_L + (\lambda I + \delta)U_0 - \gamma_L U_L - rU_L \\
 \frac{dU_0}{dt} &= -(\lambda I + \delta)U_0 + \gamma_L U_L - rU_0 \\
 \frac{dT_L}{dt} &= \alpha(\lambda I + \delta)(1 - I) + \alpha fS_L + (\lambda I + \delta)T_0 - \gamma_L T_L - (r + \sigma)T_L \\
 \frac{dT_0}{dt} &= -(\lambda I + \delta)T_0 + \gamma_L T_L - (r + \sigma)T_0 \\
 \frac{dS_L}{dt} &= -(\lambda I + \delta + f)S_L + (1 - \beta)\sigma T_L - \gamma_L S_L + r(T_L + U_L) \\
 \frac{dS_0}{dt} &= -(\lambda I + \delta)S_0 + \beta\sigma T_L + \sigma T_0 + \gamma_L S_L + r(T_0 + U_0) \\
 \frac{dP_L}{dt} &= -\gamma_L P_L \\
 \frac{dP_0}{dt} &= \gamma_L P_L
 \end{aligned} \tag{9}$$

194 starting with the initial conditions defined in (8).

195 We are assuming constant level of prophylaxis in (9). Each individual either has perfect prophylaxis during
 196 the intervention or none at all in which case they go through the usual infection pathway.

197

198 Finally, at time $t_{MDA} + p_{MDA}$, the state variables are updated as follows:

$$\begin{aligned}
 U_L(t_{MDA} + p_{MDA}) &= U_L((t_{MDA} + p_{MDA})^-) \\
 U_0(t_{MDA} + p_{MDA}) &= U_0((t_{MDA} + p_{MDA})^-) \\
 T_L(t_{MDA} + p_{MDA}) &= T_L((t_{MDA} + p_{MDA})^-) \\
 T_0(t_{MDA} + p_{MDA}) &= T_0((t_{MDA} + p_{MDA})^-) \\
 S_L(t_{MDA} + p_{MDA}) &= S_L((t_{MDA} + p_{MDA})^-) + P_L((t_{MDA} + p_{MDA})^-) \\
 S_0(t_{MDA} + p_{MDA}) &= S_0((t_{MDA} + p_{MDA})^-) + P_0((t_{MDA} + p_{MDA})^-) \\
 P_L(t_{MDA} + p_{MDA}) &= 0 \\
 P_0(t_{MDA} + p_{MDA}) &= 0
 \end{aligned} \tag{10}$$

199 and the initial model (1) is further simulated from these initial conditions.

200 Several MDA rounds can be chained using the same approach.

201 2.4 Including vector control

202 As mentioned in Champagne et al. [2022], vector control can be included in the model as a reduction of the
 203 intensity of transmission λ , following Briët et al. [2019]. The transmission parameter λ becomes $\omega\lambda$ where
 204 $\omega \in [0, 1]$ represents the intensity of vector control and can be informed by an external model for vector
 205 dynamics [Briët et al., 2019, Golumbeanu et al., 2022]. The absence of vector control corresponds to the
 206 case $\omega = 1$, and $\omega = 0$ represents perfect vector control that completely disables vector-borne transmission.
 207 By making ω time-varying, one can include a decay in vector control effectiveness, for example due to the
 208 waning of insecticide or the attrition of bednets, as in [Briët et al., 2019, Briët et al., 2020, Golumbeanu
 209 et al., 2022].

210

211 2.5 Model implementation

212 The model is implemented in R [R Core Team, 2019] as a publicly available package ([https://swisstph.
 213 github.io/VivaxModelR/](https://swisstph.github.io/VivaxModelR/)). The package enables the user to calibrate and simulate all the model versions

214 presented here (with and without delays in treatment, with and without RCD, with and without MDA).
215 The package includes tests to ensure that the back-calculations and simulations with the various models are
216 correctly implemented, as well as a user tutorial.

217

218 The ordinary differential equations solving relies on the *deSolve* package [Soetaert et al., 2021] and a
219 stochastic implementation with either Gillespie algorithm or τ -leap methodologies is provided relying on the
220 *TiPS* package [Danesh et al., 2020, 2021]. Thanks to the convergence of the stochastic version of the model
221 to its ODE counterpart for infinite population sizes [Kurtz, 1970], the back-calculation of the transmission
222 rate obtained with the ODE steady-state can be used in the stochastic model and the coherence between
223 the two model implementations is guaranteed. Such convergence is empirically verified as part of the set of
224 automated tests included in the R package.

225

226 When simulating future intervention scenarios with the model, all implementations offer the possibility
227 for the importation rate δ and the vector control term ω to be time-varying, using any empirical function
228 provided by the user as a dataset.

229 **3 Application: an illustrative example**

230 As an illustrative example, we simulate three fictitious areas with varying reported case numbers, assuming
231 perennial *P. vivax* transmission and values similar to Champagne et al. [2022], as indicated in Table 3. The
232 number of reported cases in each area increases from very low in Area 1 to moderate-high in Area 3. In
233 Area 2, it is assumed that there is no importation and all cases are contracted locally. The three areas are
234 assumed to have the same intervention parameters at baseline for case management, reactive case detection
235 and vector control. MDA being a transient intervention, it is assumed to be absent at baseline.

236

237 When calibrating the model at baseline with the chosen parameter values, malaria is sustained through
238 importation in Area 1 as R_c is smaller than 1 (cf. Table 3). On the contrary, Areas 2 and 3 experience
239 sustained local transmission ($R_c > 1$), a result that was expected by construction in Area 2 due to the
240 assumed absence of importation.

241

242 From there, five intervention scenarios are simulated, as detailed in Table 4. The first three interventions
243 are case management strengthening, reactive case detection strengthening and deployment of indoor resid-
244 ual spraying (IRS): the parameters corresponding to these interventions are detailed in Table 4 and their
245 impact on malaria prevalence is presented in Figure 4. In this example, case management strengthening
246 always leads to a large decrease in malaria prevalence although it is not sufficient to reach elimination.
247 Reactive case detection has a much larger impact in areas with higher endemicity as there are more cases
248 to be detected. In the three examples considered, using the time-varying targeting ratio from Chitnis et al.
249 [2019] leads to stronger prevalence reductions than the fixed value, as the targeting ratio increases with
250 decreasing prevalence and hence accelerate the decrease in malaria trends. Finally, IRS leads to important
251 reductions in malaria prevalence, but because its 6-month effectiveness duration, the intervention needs
252 to be redeployed regularly to sustain the gains. In this particular example, improvements in case manage-
253 ments have a greater impact on prevalence compared to the introduction of IRS or the strengthening of RCD.

254

255 The last two scenarios include MDA with and without PQ for radical cure. Because of the high vari-
256 ability expected when the model reaches low case numbers, the stochastic version of the model is used, with
257 100 independent simulation replicates. The effect of MDA is transient, and malaria transmission bounces
258 back to initial prevalence levels when the intervention is interrupted. As expected, targeting the liver-stage
259 reservoir with PQ increases the prevalence reduction achieved. In the scenario with very low transmission
260 (Area 1), elimination is not reached within the 7 years simulated because transmission is sustained with
261 importation, elimination being defined in this example as a whole year with zero cases (including reported
262 and unreported). Other definitions of malaria elimination in the presence of importation, distinguishing
263 local, indigenous and imported cases [Das et al., 2022b] could also be explored but are beyond the scope of
264 the current work. In the scenario without importation (Area 2) and with PQ MDA, elimination in 7 years

Baseline parameters	Area 1	Area 2	Area 3
Setting-specific data			
Reported cases per year	6	95	540
Imported cases per year	1	0	27
Population size	5000	5000	5000
Setting-specific parameters at baseline			
Access to care (a)	0.5	0.5	0.5
Proportion of infections effectively cured for blood stage (α)	$a * s * d$	$a * s * d$	$a * s * d$
Radical cure (β)	$0.86 * \epsilon$	$0.86 * \epsilon$	$0.86 * \epsilon$
Observation rate (ρ)	α	α	α
Average treatment delay ($1/\sigma$, in days)	10	10	10
Vector control (ω , $\omega = 1$ corresponds to the absence of control)	1	1	1
RCD: max. index cases investigated (ι , per week per 5000 inh.)	50	50	50
RCD: number of individuals investigated per index case (ν)	5	5	5
RCD: targeting ratio (τ)	5	5	5
RCD: probability to detect and treat a case (η)	d	d	d
MDA: coverage (c_{MDA})	0	0	0
MDA: radical cure treatment (β_{MDA})	0	0	0
Fixed parameters			
Relapse frequency (f , in days ⁻¹)	1/223 [White et al., 2016]		
Clearance rate (r , in days ⁻¹)	1/60 [White et al., 2016]		
PQ efficacy (ϵ)	0.76 [Champagne et al., 2022]		
RDT sensitivity (d)	0.95 [Abba et al., 2014]		
Symptomatic proportion (s)	0.3 [Cheng et al., 2015]		
Estimated reproduction numbers			
R_0	0.79	1.38	1.39
R_c	0.64	1.11	1.12

Table 3: Model parameters and data at baseline for three fictitious areas.

Scenario	Description
Baseline	All parameters remain unchanged
Improved case management	Access to care is increased to 80% ($\alpha = 0.8 * s * d$) Radical cure is increased to 90% ($\beta = 0.9 * \epsilon$) Delays in treatment are reduced ($1/\sigma = 5$)
Increased RCD	The number of investigations per index case is increased ($\nu = 10$)
IRS	IRS with Bendiocarb is deployed every year with 60% coverage, for a vector comparable to <i>An. albimanus</i> [Briët et al., 2019] ($\omega = 0.56$ at deployment, reverting gradually to 1 over a 6-month period, calculated as in [Briët et al., 2019] with [Golumbeanu et al., 2022])
MDA, no PQ	MDA is deployed in 3 rounds spaced by 1 year, with 30 days prophylaxis duration reaching 80% coverage ($c_{MDA} = 0.8$), without treatment for radical cure ($\beta_{MDA} = 0$)
MDA, with PQ	MDA is deployed in 3 rounds spaced by 1 year with 30 days prophylaxis duration reaching 80% coverage ($c_{MDA} = 0.8$), with treatment for radical cure ($\beta_{MDA} = 0.5$)

Table 4: Parameter values of the intervention scenarios simulated




Figure 4: Effect of various intervention scenarios on *P. vivax* prevalence, applied in three artificial settings. The parameter values corresponding to each scenario can be found in Table 4.

265 is reached in 11% of the simulations, highlighting the difficulty of reaching this outcome.

266




Figure 5: Effect of MDA scenarios on *P. vivax* prevalence, applied in three artificial settings. The parameter values corresponding to each scenario can be found in Table 4. The lines represent the median of 100 independent stochastic simulations, while the shaded area represent the 95% uncertainty intervals.

4 Discussion

In this work, we presented an extended compartmental model for *P. vivax* dynamics at the population level that includes four commonly deployed interventions, namely treatments, vector control, reactive case detection and mass drug administration. It can be calibrated in each setting of interest at the local level using the observed incidence at steady-state, thus providing estimates of transmission potential. The setting-specific model can then be used to compare the impact of various intervention strategies and identify the most promising ones. The model can be simulated in both the deterministic and the stochastic framework and it is readily implemented as a publicly available R package.

Thanks to its stochastic implementation [Danesh et al., 2020, 2021], the model can be used to compute elimination probabilities and timelines, which are useful outcomes to compare malaria intervention strategies in low-endemicity settings. Additionally, the inclusion of demographic stochasticity opens the possibility to use the model for small population sizes, as required to represent *P. vivax* dynamics at local scales.

The model incorporates the effect of routine malaria treatment on transmission through three parameters: the proportion of blood-stage infections that are treated, the proportion of treated cases that achieve radical cure of the liver-stage parasites and the duration of infectivity for treated cases. These three aspects are important components of health system strengthening strategies and the possibility to compare improvements in these three dimensions simultaneously or independently can provide useful information for decision-makers. Nonetheless, it is important to note that the model is very sensitive to the value of baseline case management parameters [Champagne et al., 2022] and the modelled impact of case management strategies relies heavily on the availability and quality of data on the health system at the spatial scale of interest.

The mathematical representation of RCD relies on the definition of a targeting ratio, and thus does not include mechanistically the effect of case clustering as would be the case in spatially-explicit individual-based models [Gerardin et al., 2017]. Therefore, similarly to Chitnis et al. [2019], Reiker et al. [2019], Das et al. [2022a], it is necessary to parameterise the targeting ratio using setting-specific data [Das et al., 2022a] or by choosing appropriate assumptions adapted to the local context. Epidemiological knowledge of infection risk factors to evaluate if such a strategy is suitable in a given setting is therefore considered as a prerequisite before using the model. For example, in countries where *P. vivax* infection is mainly driven by occupational exposure (e.g. working in the forest), the investigation of the neighborhood of index cases might be less efficient compared to occupational screening [Mukaka et al., 2021]: this effect could be represented with a smaller targeting ratio. This appreciation is therefore left to the user when choosing the appropriate value for targeting ratio in the setting of interest. Nonetheless, if data on the source of case reporting (via RCD or via other detection channels) is available, the value of the targeting ratio can be quantified at baseline using the back-calculation methodology presented here. The objective of the current model is therefore not to investigate if RCD has the capacity to detect cases in general, but rather to evaluate its impact in relation to other interventions and for various implementation designs.

In line with other modelling work [Robinson et al., 2015, Pemberton-Ross et al., 2017, White et al., 2018, Obadia et al., 2022] and with the available epidemiological evidence [Shah et al., 2021], MDA is represented as an instantaneous shock on the state variables without affecting the model parameters. Therefore, its effect is transient by construction and malaria dynamics are expected to revert to their previous equilibrium except in the stochastic case if elimination is reached, or if accompanied by sustainable changes such as increased intervention coverages or environmental modifications. Decay in the effectiveness of prophylaxis is not explicitly modelled, rather the model assumes a constant level of protection during the time of prophylaxis. This simplification should not strongly affect the annual results for drugs with prophylaxis duration of 15 to 30 days. Nonetheless, the model could also be extended to include parametric decay forms.

Mosquito dynamics are not directly included in the model and the effect of vector control is represented as a reduction of the human-to-human transmission intensity. This simplifying assumption is chosen because the time scale of vector dynamics is much shorter than the one of human dynamics, such that in a low en-

320 demicity setting where the proportion of infectious host is small, the parasite dynamics can be approximated
321 by an SIS-like model [Smith and McKenzie, 2004]. Additionally, using the model by Golumbeanu et al.
322 [2022] enables the user to account for differences in vector control efficacy due to mosquito species biological
323 characteristics, intervention type or the proportion of time that individuals spend indoors or in bed [Briët
324 et al., 2019], whose importance can be crucial, especially in elimination settings outside of Africa.

325
326 Seasonality is not included in the model, which is suitable for perennial settings or when studying annual
327 data and interventions that do not have seasonal effects. Nonetheless, the R package implementation of
328 the model offers the possibility to include a seasonal forcing into the transmission rate via the time-varying
329 parameter ω when simulating disease dynamics over time. Adapting the back-calculation methodology and
330 reproduction number definition to the seasonal case [Bacaër, 2007] is however outside the scope of the current
331 work.

332
333 The model is a simplified representation of reality and has therefore a certain number of limitations.
334 Firstly, the chosen representation of treatment delays assumes that host infectiousness to mosquitoes is
335 constant over time, which is an important simplification in regard to the complex life cycle of the malaria
336 parasites [Gaspoz and al., in prep] and the relaxation of this assumption will be the object of future work. In
337 addition, delays in access to treatment were represented with exponential durations via the ODE formalism
338 and not fixed durations as would have been the case with delay differential equations [Kim et al., 2021, Tian
339 et al., 2022]. Nonetheless, the chosen formalism of the model presents some similarities with a model based
340 on delayed-differential equations, as illustrated in Appendix A for a simpler model with perfect radical cure.

341
342 Moreover, because of its emphasis on implementation simplicity, this model makes some additional sim-
343 plifications in the biological depiction of *P. vivax*. Importantly, the model does not include any form of
344 immunity, an assumption which is only acceptable in settings with low to moderate transmission level, as in
345 [Champagne et al., 2022]. Relapses are modelled to occur at a constant rate, based on [White et al., 2016]
346 which relied on [White et al., 2014], although the underlying mechanism could be represented with increased
347 details [Mehra et al., 2022]. This compartmental model also relies on various homogeneity assumptions,
348 as differences in infectiousness or susceptibility related to severity levels or age groups are not represented.
349 Finally, the back-calculation methodology for baseline calibration relies on the steady state of the model,
350 nonetheless other statistical methods could be used instead when temporal data is available [Chatzilena
351 et al., 2019].

352
353 Despite these limitations, this model provides a useful additional tool to support country-specific decision
354 making in the choice of interventions to deploy in various areas. Thanks to its analytical foundations and its
355 simplicity of implementation, this model can support decision making on malaria strategies in a rapid and
356 transparent manner.

357 Data availability

358 The computer code utilized in this manuscript is available at: <https://github.com/SwissTPH/VivaxModelR>.

359 Author contributions

360 **Clara Champagne:** Conceptualization, Methodology, Software, Formal Analysis, Investigation, Writing -
361 Original Draft. **Maximilian Gerhards:** Conceptualization, Methodology, Formal Analysis, Investigation,
362 Writing - Original Draft. **Justin Lana:** Conceptualization, Investigation, Writing - Review & Editing.
363 **Arnaud Le Menach:** Conceptualization, Writing - Review & Editing, Project Administration, Funding
364 Acquisition. **Emilie Pothin** Conceptualization, Methodology, Writing - Review & Editing, Project Admin-
365 istration, Funding Acquisition.

366 Acknowledgements

367 The authors want to thank Gonché Danesh for her help with the *TiPS* package [Danesh et al., 2020,
368 2021], Roland Goers for code review, Jeanne Lemant for support in the parameterisation of IRS and Nakul
369 Chitnis and Aatreyee M. Das for discussions on reactive case detection and for sharing their manuscript
370 ahead of publication. Code development was performed on the infrastructure provided by sciCORE (<http://scicore.unibas.ch/>), scientific computing center at University of Basel.

371
372
373 This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [OPP1109772/INV-
374 008108]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License
375 has already been assigned to the Author Accepted Manuscript version that might arise from this submission.

376 Declarations of interest

377 None.

378 References

- 379 K. Abba, A. J. Kirkham, P. L. Olliaro, J. J. Deeks, S. Donegan, P. Garner, and Y. Takwoingi. Rapid diagnos-
380 tic tests for diagnosing uncomplicated non-falciparum or *Plasmodium vivax* malaria in endemic countries.
381 (12), 2014. ISSN 1465-1858. doi: 10.1002/14651858.CD011431. URL <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011431/full>. Publisher: John Wiley & Sons, Ltd.
- 382
383 P. L. Alonso. The role of mass drug administration of antimalarials. 103(2):1–2, 2020. ISSN 0002-9637,
384 1476-1645. doi: 10.4269/ajtmh.20-0729. URL https://www.ajtmh.org/view/journals/tpmd/103/2_Suppl/article-p1.xml. Publisher: The American Society of Tropical Medicine and Hygiene Section:
385 The American Journal of Tropical Medicine and Hygiene.
386
- 387 J. Arino and P. van den Driessche. Time delays in epidemic models: modeling and numerical considerations.
388 In *Delay Differential Equations and Applications*. Springer Verlag, 2006.
- 389 N. Bacaër. Approximation of the basic reproduction number r_0 for vector-borne diseases with a periodic
390 vector population. 69(3):1067–1091, 2007. ISSN 0092-8240. doi: 10.1007/s11538-006-9166-9.
- 391 V. S. Balakrishnan. El salvador’s malaria elimination success story. 2(5):e181, 2021. ISSN 2666-5247.
392 doi: 10.1016/S2666-5247(21)00096-3. URL [https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247\(21\)00096-3/abstract](https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00096-3/abstract). Publisher: Elsevier.
- 393
394 Q. Bassat, M. Velarde, I. Mueller, J. Lin, T. Leslie, C. Wongsrichanalai, and J. K. Baird. Key knowledge
395 gaps for plasmodium vivax control and elimination. 95(6):62–71, 2016. ISSN 1476-1645. doi: 10.4269/
396 ajtmh.16-0180.

- 397 S. Bhatt, D. J. Weiss, E. Cameron, D. Bisanzio, B. Mappin, U. Dalrymple, K. Battle, C. L. Moyes, A. Henry,
398 P. A. Eckhoff, E. A. Wenger, O. Briet, M. A. Penny, T. A. Smith, A. Bennett, J. Yukich, T. P. Eisele,
399 J. T. Griffin, C. A. Fergus, M. Lynch, F. Lindgren, J. M. Cohen, C. L. J. Murray, D. L. Smith, S. I. Hay,
400 R. E. Cibulskis, and P. W. Gething. The effect of malaria control on plasmodium falciparum in africa
401 between 2000 and 2015. 526(7572):207–211, 2015. ISSN 1476-4687 (Electronic) 0028-0836 (Linking). doi:
402 10.1038/nature15535.
- 403 O. Briet, H. Koenker, L. Norris, R. Wiegand, J. Vanden Eng, A. Thackeray, J. Williamson, J. E. Gimnig,
404 F. Fortes, M. Akogbeto, A. W. Yadouleton, M. Ombok, M. N. Bayoh, T. Mzilahowa, A. P. Abílio,
405 S. Mabunda, N. Cuamba, E. Diouf, L. Konaté, B. Hamainza, C. Katebe-Sakala, G. Ponce de León,
406 K. Asamoah, A. Wolkon, S. C. Smith, I. Swamidoss, M. Green, S. Gueye, J. Mihigo, J. Morgan, E. Dotson,
407 A. S. Craig, K. R. Tan, R. A. Wirtz, and T. Smith. Attrition, physical integrity and insecticidal activity
408 of long-lasting insecticidal nets in sub-saharan africa and modelling of their impact on vectorial capacity.
409 19(1):310, 2020. ISSN 1475-2875. doi: 10.1186/s12936-020-03383-6. URL [https://malariajournal.
410 biomedcentral.com/articles/10.1186/s12936-020-03383-6](https://malariajournal.biomedcentral.com/articles/10.1186/s12936-020-03383-6).
- 411 O. J. T. Briët, D. E. Impoinvil, N. Chitnis, E. Pothin, J. F. Lemoine, J. Frederic, and T. A. Smith. Models
412 of effectiveness of interventions against malaria transmitted by anopheles albimanus. 18(1):263, 2019.
413 ISSN 1475-2875. doi: 10.1186/s12936-019-2899-3. URL [https://malariajournal.biomedcentral.com/
414 articles/10.1186/s12936-019-2899-3](https://malariajournal.biomedcentral.com/articles/10.1186/s12936-019-2899-3).
- 415 R. A. Burton, J. E. R. Chévez, M. Sauerbrey, C. Guinovart, A. Hartley, G. Kirkwood, M. Boslego, M. E.
416 Gavidia, J. E. Alemán Escobar, R. Turkel, R. W. Steketee, L. Slutsker, K. Schneider, and C. C. K.
417 Campbell. Factors associated with the rapid and durable decline in malaria incidence in el salvador,
418 1980–2017. 99(1):33–42, 2018. ISSN 0002-9637. doi: 10.4269/ajtmh.17-0629. URL [https://www.ncbi.
419 nlm.nih.gov/pmc/articles/PMC6085812/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085812/).
- 420 C. Champagne, M. Gerhards, J. Lana, B. G. Espinosa, C. Bradley, O. González, J. M. Cohen, A. Le Men-
421 ach, M. T. White, and E. Pothin. Using observed incidence to calibrate the transmission level of a
422 mathematical model for Plasmodium vivax dynamics including case management and importation. *Math-*
423 *ematical Biosciences*, page 108750, Jan. 2022. ISSN 0025-5564. doi: 10.1016/j.mbs.2021.108750. URL
424 <https://www.sciencedirect.com/science/article/pii/S0025556421001541>.
- 425 A. Chatzilena, E. van Leeuwen, O. Ratmann, M. Baguelin, and N. Demiris. Contemporary statistical infer-
426 ence for infectious disease models using stan. page 100367, 2019. ISSN 1755-4365. doi: 10.1016/j.epidem.
427 2019.100367. URL <http://www.sciencedirect.com/science/article/pii/S1755436519300325>.
- 428 Q. Cheng, J. Cunningham, and M. L. Gatton. Systematic review of sub-microscopic p. vivax infections:
429 Prevalence and determining factors. 9(1):e3413, 2015. ISSN 1935-2735. doi: 10.1371/journal.pntd.
430 0003413. URL <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003413>.
431 Publisher: Public Library of Science.
- 432 N. Chitnis, P. Pemberton-Ross, J. Yukich, B. Hamainza, J. Miller, T. Reiker, T. P. Eisele, and T. A.
433 Smith. Theory of reactive interventions in the elimination and control of malaria. *Malaria Journal*, 18
434 (1):266, Aug. 2019. ISSN 1475-2875. doi: 10.1186/s12936-019-2882-z. URL [https://doi.org/10.1186/
435 s12936-019-2882-z](https://doi.org/10.1186/s12936-019-2882-z).
- 436 C. S. Chu and N. J. White. The prevention and treatment of plasmodium vivax malaria. 18(4):e1003561, 2021.
437 ISSN 1549-1676. doi: 10.1371/journal.pmed.1003561. URL [https://journals.plos.org/plosmedicine/
438 article?id=10.1371/journal.pmed.1003561](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003561). Publisher: Public Library of Science.
- 439 J. M. Cohen, A. Le Menach, E. Pothin, T. P. Eisele, P. W. Gething, P. A. Eckhoff, B. Moonen, A. Schapira,
440 and D. L. Smith. Mapping multiple components of malaria risk for improved targeting of elimination
441 interventions. 16(1):459, 2017. ISSN 1475-2875. doi: 10.1186/s12936-017-2106-3. URL [https://doi.
442 org/10.1186/s12936-017-2106-3](https://doi.org/10.1186/s12936-017-2106-3).

- 443 G. Danesh, E. Saulnier, O. Gascuel, M. Choisy, and S. Alizon. Simulating trajectories and phylogenies from
444 population dynamics models with TiPS, 2020. URL [https://www.biorxiv.org/content/10.1101/2020.](https://www.biorxiv.org/content/10.1101/2020.11.09.373795v1)
445 [11.09.373795v1](https://www.biorxiv.org/content/10.1101/2020.11.09.373795v1). Company: Cold Spring Harbor Laboratory Distributor: Cold Spring Harbor Laboratory
446 Label: Cold Spring Harbor Laboratory Section: New Results Type: article.
- 447 G. Danesh, E. Saulnier, M. Choisy, and S. Alizon. TiPS: Trajectories and phylogenies simulator, 2021. URL
448 <https://CRAN.R-project.org/package=TiPS>.
- 449 A. M. Das, M. W. Hetzel, J. O. Yukich, L. Stuck, B. S. Fakih, A.-w. H. Al-mafazy, A. Ali, and N. Chitnis.
450 The impact of human mobility and reactive case detection on malaria transmission in zanzibar. *medRxiv*,
451 2022a. doi: 10.1101/2022.03.29.22273100. URL [https://www.medrxiv.org/content/10.1101/2022.03.](https://www.medrxiv.org/content/10.1101/2022.03.29.22273100v1)
452 [29.22273100v1](https://www.medrxiv.org/content/10.1101/2022.03.29.22273100v1).
- 453 A. M. Das, M. W. Hetzel, J. O. Yukich, L. Stuck, B. S. Fakih, A.-w. H. Al-mafazy, A. Ali, and N. Chit-
454 nis. Modelling the impact of interventions on imported, introduced and indigenous malaria infections
455 in Zanzibar, Tanzania, Sept. 2022b. URL [https://www.medrxiv.org/content/10.1101/2022.09.06.](https://www.medrxiv.org/content/10.1101/2022.09.06.22279643v1)
456 [22279643v1](https://www.medrxiv.org/content/10.1101/2022.09.06.22279643v1). Pages: 2022.09.06.22279643.
- 457 N. M. Douglas, N. M. Anstey, B. J. Angus, F. Nosten, and R. N. Price. Artemisinin combination therapy
458 for vivax malaria. 10(6):405–416, 2010. ISSN 14733099. doi: 10.1016/S1473-3099(10)70079-7. URL
459 <https://linkinghub.elsevier.com/retrieve/pii/S1473309910700797>.
- 460 C. Emerson, J. Meline, A. Linn, J. Wallace, B. K. Kapella, M. Venkatesan, and R. Steketee. End malaria
461 faster: Taking lifesaving tools beyond “access” to “reach” all people in need. 10(2), 2022. ISSN 2169-
462 575X. doi: 10.9745/GHSP-D-22-00118. URL <https://www.ghspjournal.org/content/10/2/e2200118>.
463 Publisher: Global Health: Science and Practice Section: COMMENTARIES.
- 464 K. Galactionova, F. Tediosi, D. de Savigny, T. Smith, and M. Tanner. Effective coverage and systems
465 effectiveness for malaria case management in sub-saharan african countries. 10(5):e0127818, 2015. ISSN
466 1932-6203. doi: 10.1371/journal.pone.0127818. URL [https://dx.plos.org/10.1371/journal.pone.](https://dx.plos.org/10.1371/journal.pone.0127818)
467 [0127818](https://dx.plos.org/10.1371/journal.pone.0127818).
- 468 V. Gaspoz and al. The impact of delayed access to treatment on malaria transmission for p. vivax and p.
469 falciparum malaria: An evaluation using mathematical models. in prep.
- 470 J. Gerardin, C. A. Bever, D. Bridenbecker, B. Hamainza, K. Silumbe, J. M. Miller, T. P. Eisele, P. A.
471 Eckhoff, and E. A. Wenger. Effectiveness of reactive case detection for malaria elimination in three
472 archetypical transmission settings: a modelling study. 16(1):248, 2017. ISSN 1475-2875. doi: 10.1186/
473 [s12936-017-1903-z](https://doi.org/10.1186/s12936-017-1903-z). URL <https://doi.org/10.1186/s12936-017-1903-z>.
- 474 M. Golumbeanu, O. Briet, N. Chitnis, M. Penny, M. Sinka, and T. A. Smith. AnophelesModel: assessing
475 the impact of vector control interventions according to mosquito bionomics and human activity, 2022.
- 476 M. W. Hetzel and N. Chitnis. Reducing malaria transmission with reactive focal interventions. *The*
477 *Lancet*, 395(10233):1317–1319, Apr. 2020. ISSN 0140-6736, 1474-547X. doi: 10.1016/S0140-6736(20)
478 30678-4. URL [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30678-4/](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30678-4/abstract)
479 [abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30678-4/abstract). Publisher: Elsevier.
- 480 J. H. Kim, J. Suh, W. J. Lee, H. Choi, J.-D. Kim, C. Kim, J. Y. Choi, R. Ko, H. Kim, J. Lee, and
481 J. S. Yeom. Modelling the impact of rapid diagnostic tests on plasmodium vivax malaria in south korea: a
482 cost–benefit analysis. 6(2):e004292, 2021. ISSN 2059-7908. doi: 10.1136/bmjgh-2020-004292. URL [https:](https://gh.bmj.com/content/6/2/e004292)
483 [//gh.bmj.com/content/6/2/e004292](https://gh.bmj.com/content/6/2/e004292). Publisher: BMJ Specialist Journals Section: Original research.
- 484 T. G. Kurtz. Solutions of ordinary differential equations as limits of pure jump markov processes. 7(1):
485 49–58, 1970. ISSN 0021-9002. doi: 10.2307/3212147. URL <https://www.jstor.org/stable/3212147>.
486 Publisher: Applied Probability Trust.

- 487 S. Mehra, E. Stadler, D. Khoury, J. M. McCaw, and J. A. Flegg. Hypnozoite dynamics for plasmodium vivax
488 malaria: The epidemiological effects of radical cure. 537:111014, 2022. ISSN 0022-5193. doi: 10.1016/j.
489 jtb.2022.111014. URL <https://www.sciencedirect.com/science/article/pii/S0022519322000121>.
- 490 A. Monroe, S. Moore, F. Okumu, S. Kiware, N. F. Lobo, H. Koenker, E. Sherrard-Smith, J. Gimnig, and
491 G. F. Killeen. Methods and indicators for measuring patterns of human exposure to malaria vectors. 19
492 (1):207, 2020. ISSN 1475-2875. doi: 10.1186/s12936-020-03271-z.
- 493 M. Mukaka, P. Peerawaranun, D. M. Parker, L. Kajechiwa, F. H. Nosten, T.-N. Nguyen, T. T. Hien,
494 R. Tripura, T. J. Peto, K. Phommason, M. Mayxay, P. N. Newton, M. Imwong, N. P. J. Day, A. M.
495 Dondorp, N. J. White, and L. von Seidlein. Clustering of malaria in households in the greater mekong
496 subregion: operational implications for reactive case detection. 20(1):351, 2021. ISSN 1475-2875. doi:
497 10.1186/s12936-021-03879-9. URL <https://doi.org/10.1186/s12936-021-03879-9>.
- 498 T. Obadia, N. Nekkab, L. J. Robinson, C. Drakeley, I. Mueller, and M. T. White. Developing sero-
499 diagnostic tests to facilitate plasmodium vivax serological test-and-treat approaches: modeling the
500 balance between public health impact and overtreatment. 20(1):98, 2022. ISSN 1741-7015. doi:
501 10.1186/s12916-022-02285-5. URL <https://doi.org/10.1186/s12916-022-02285-5>.
- 502 B. N. Owen, M. Winkel, C. Bonnington, A. Nuwa, J. Achan, J. Opigo, J. K. Tibenderana, and E. Pothin.
503 Dynamical malaria modeling as a tool for bold policy-making. pages 1–1, 2022. ISSN 1546-170X. doi: 10.
504 1038/s41591-022-01756-9. URL <https://www.nature.com/articles/s41591-022-01756-9>. Publisher:
505 Nature Publishing Group.
- 506 P. Pemberton-Ross, N. Chitnis, E. Pothin, and T. A. Smith. A stochastic model for the probability of
507 malaria extinction by mass drug administration. *Malaria Journal*, 16(1):376, Dec. 2017. ISSN 1475-
508 2875. doi: 10.1186/s12936-017-2010-x. URL [http://malariajournal.biomedcentral.com/articles/
509 10.1186/s12936-017-2010-x](http://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-2010-x).
- 510 R. Perera, A. Caldera, and A. R. Wickremasinghe. Reactive case detection (RACD) and foci investigation
511 strategies in malaria control and elimination: a review. 19(1):401, 2020. ISSN 1475-2875. doi: 10.1186/
512 s12936-020-03478-0. URL <https://doi.org/10.1186/s12936-020-03478-0>.
- 513 E. Poirot, J. Skarbinski, D. Sinclair, S. P. Kachur, L. Slutsker, and J. Hwang. Mass drug administration
514 for malaria. (12), 2013. ISSN 1465-1858. doi: 10.1002/14651858.CD008846.pub2. URL [https://www.
515 cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008846.pub2/full](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008846.pub2/full). Publisher: John Wiley &
516 Sons, Ltd.
- 517 R Core Team. R: A language and environment for statistical computing., 2019. URL [https://www.
518 R-project.org/](https://www.R-project.org/).
- 519 T. Reiker, N. Chitnis, and T. Smith. Modelling reactive case detection strategies for interrupting transmission
520 of Plasmodium falciparum malaria. *Malaria Journal*, 18(1):259, July 2019. ISSN 1475-2875. doi: 10.1186/
521 s12936-019-2893-9. URL <https://doi.org/10.1186/s12936-019-2893-9>.
- 522 L. J. Robinson, R. Wampfler, I. Betuela, S. Karl, M. T. White, C. S. N. Li Wai Suen, N. E. Hofmann,
523 B. Kinboro, A. Waltmann, J. Brewster, L. Lorry, N. Tarongka, L. Samol, M. Silkey, Q. Bassat, P. M. Siba,
524 L. Schofield, I. Felger, and I. Mueller. Strategies for understanding and reducing the plasmodium vivax and
525 plasmodium ovale hypnozoite reservoir in papua new guinean children: A randomised placebo-controlled
526 trial and mathematical model. 12(10), 2015. ISSN 1549-1277. doi: 10.1371/journal.pmed.1001891. URL
527 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624431/>.
- 528 M. P. Shah, J. Hwang, L. Choi, K. A. Lindblade, S. P. Kachur, and M. Desai. Mass drug administration
529 for malaria. (9), 2021. ISSN 1465-1858. doi: 10.1002/14651858.CD008846.pub3. URL [https://www.
530 cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008846.pub3/full](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008846.pub3/full). Publisher: John Wiley &
531 Sons, Ltd.
- 532 D. L. Smith and F. E. McKenzie. Statics and dynamics of malaria infection in anopheles mosquitoes. 3(1):
533 13, 2004. ISSN 1475-2875. doi: 10.1186/1475-2875-3-13.

- 534 K. Soetaert, T. Petzoldt, and R. W. Setzer. Package deSolve: Solving initial value differential equations in
535 r, 2021.
- 536 K. Thriemer, B. Ley, and L. v. Seidlein. Towards the elimination of plasmodium vivax malaria: Implementing
537 the radical cure. 18(4):e1003494, 2021. ISSN 1549-1676. doi: 10.1371/journal.pmed.1003494. URL
538 <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003494>. Publisher:
539 Public Library of Science.
- 540 H. Tian, N. Li, Y. Li, M. U. G. Kraemer, H. Tan, Y. Liu, Y. Li, B. Wang, P. Wu, B. Cazelles, J. Lourenço,
541 D. Gao, D. Sun, W. Song, Y. Li, O. G. Pybus, G. Wang, and C. Dye. Malaria elimination on hainan
542 island despite climate change. 2(1):1–9, 2022. ISSN 2730-664X. doi: 10.1038/s43856-022-00073-z. URL
543 <https://www.nature.com/articles/s43856-022-00073-z>. Number: 1 Publisher: Nature Publishing
544 Group.
- 545 P. van den Driessche and J. Watmough. Reproduction numbers and sub-threshold endemic equi-
546 libria for compartmental models of disease transmission. 180(1):29–48, 2002. ISSN 0025-5564.
547 doi: 10.1016/S0025-5564(02)00108-6. URL [http://www.sciencedirect.com/science/article/pii/](http://www.sciencedirect.com/science/article/pii/S0025556402001086)
548 [S0025556402001086](http://www.sciencedirect.com/science/article/pii/S0025556402001086).
- 549 A. M. van Eijk, L. Ramanathapuram, P. L. Sutton, D. Kanagaraj, G. Sri Lakshmi Priya, S. Ravishankaran,
550 A. Asokan, N. Tandel, A. Patel, N. Desai, R. Singh, S. A. Sullivan, J. M. Carlton, H. C. Srivastava, and
551 A. Eapen. What is the value of reactive case detection in malaria control? A case-study in India and
552 a systematic review. *Malaria Journal*, 15, Feb. 2016. ISSN 1475-2875. doi: 10.1186/s12936-016-1120-1.
553 URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744450/>.
- 554 M. T. White, S. Karl, K. E. Battle, S. I. Hay, I. Mueller, and A. C. Ghani. Modelling the contribution of the
555 hypnozoite reservoir to plasmodium vivax transmission. 3:e04692, 2014. ISSN 2050-084X. doi: 10.7554/
556 eLife.04692. URL <https://doi.org/10.7554/eLife.04692>. Publisher: eLife Sciences Publications, Ltd.
- 557 M. T. White, G. Shirreff, S. Karl, A. C. Ghani, and I. Mueller. Variation in relapse frequency and the
558 transmission potential of plasmodium vivax malaria. 283(1827):20160048, 2016. doi: 10.1098/rspb.2016.
559 0048. URL <https://royalsocietypublishing.org/doi/10.1098/rspb.2016.0048>. Publisher: Royal
560 Society.
- 561 M. T. White, P. Walker, S. Karl, M. W. Hetzel, T. Freeman, A. Waltmann, M. Laman, L. J. Robinson,
562 A. Ghani, and I. Mueller. Mathematical modelling of the impact of expanding levels of malaria control
563 interventions on plasmodium vivax. 9(1):1–10, 2018. ISSN 2041-1723. doi: 10.1038/s41467-018-05860-8.
564 URL <https://www.nature.com/articles/s41467-018-05860-8>. Number: 1 Publisher: Nature Pub-
565 lishing Group.
- 566 World Health Organization. Zeroing in on malaria elimination, 2021. URL [https://www.who.int/](https://www.who.int/publications-detail-redirect/9789240024359)
567 [publications-detail-redirect/9789240024359](https://www.who.int/publications-detail-redirect/9789240024359).
- 568 World Health Organization. Recommendations on malaria elimination, 2022a. URL [https://www.who.int/](https://www.who.int/teams/global-malaria-programme/elimination/recommendations-on-malaria-elimination)
569 [teams/global-malaria-programme/elimination/recommendations-on-malaria-elimination](https://www.who.int/teams/global-malaria-programme/elimination/recommendations-on-malaria-elimination).
- 570 World Health Organization. World malaria report 2022, 2022b. URL [https://www.who.int/teams/](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022)
571 [global-malaria-programme/reports/world-malaria-report-2022](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022).
- 572 World Health Organization, Global Malaria Programme, and World Health Organization. Control and
573 elimination of plasmodium vivax malaria: a technical brief, 2015a. URL [http://apps.who.int/iris/](http://apps.who.int/iris/bitstream/10665/181162/1/9789241509244_eng.pdf?ua=1&ua=1)
574 [bitstream/10665/181162/1/9789241509244_eng.pdf?ua=1&ua=1](http://apps.who.int/iris/bitstream/10665/181162/1/9789241509244_eng.pdf?ua=1&ua=1). OCLC: 915959932.
- 575 World Health Organization, World Health Organization, and Global Malaria Programme. *Global technical*
576 *strategy for malaria, 2016-2030*. 2015b. ISBN 978-92-4-156499-1. OCLC: 921272942.

577 **A Including delay in treatment access: rationale for the chosen** 578 **model**

579 The model without treatment delays [Champagne et al., 2022] is defined by the following system of ordinary
580 differential equations:

$$\begin{aligned}
 \frac{dI_L}{dt} &= (1 - \alpha)(\lambda(I_L + I_0) + \delta)(S_0 + S_L) + (\lambda(I_L + I_0) + \delta)I_0 + (1 - \alpha)fS_L - \gamma_L I_L - rI_L \\
 \frac{dI_0}{dt} &= -(\lambda(I_L + I_0) + \delta)I_0 + \gamma_L I_L - rI_0 \\
 \frac{dS_L}{dt} &= -(1 - \alpha(1 - \beta))(\lambda(I_L + I_0) + \delta + f)S_L + \alpha(1 - \beta)(\lambda(I_0 + I_L) + \delta)S_0 - \gamma_L S_L + rI_L \\
 \frac{dS_0}{dt} &= -(1 - \alpha\beta)(\lambda(I_L + I_0) + \delta)S_0 + (\lambda(I_0 + I_L) + \delta)(\alpha\beta S_L) + \alpha\beta fS_L + \gamma_L S_L + rI_0
 \end{aligned}
 \tag{11}$$

581 In this model, the effect of treatment is instantaneous, however, in reality individuals do not get treated
582 instantaneously. Therefore, we aim to modify the model to include some time delay between infection and
583 clearance of the parasite for treated individuals. We define $I := 1 - S_L + S_0$ the proportion of individuals
584 with blood-stage infections and will focus on the case with $\beta = 1$ (perfect radical cure for treated individuals).
585

586 Following the approach of Arino and Van den Driessche [Arino and van den Driessche, 2006] (vaccination
587 model), we have the following equation for I :

$$I(t) = I^{Start}(t) + \int_0^t [(\lambda I(u) + \delta)(1 - I(u)) + fS_L(u)] P(t - u) e^{-(t-u)r} du
 \tag{12}$$

588 where $P(t - u)$ is the proportion of those who were infected at time u and have not been effectively treated
589 at time t . Two choices for the function P are explored in the following sections: the first one represents a
590 delay with constant duration and the second one a delay with geometric duration.
591

592 **A.1 Delay with constant duration: using delay differential equations**

If effective treatment is applied to a proportion α after a fixed time σ^{-1} , the function P is a step function

$$P(t) = \begin{cases} 1 & \text{for } t < \sigma^{-1} \\ 1 - \alpha & \text{for } t \geq \sigma^{-1} \end{cases} .$$

593 Inserting in the equation (12) we obtain the following equation:

$$\begin{aligned}
 I(t) &= I^{Start}(t) + \int_{t-\sigma^{-1}}^t [(\lambda I(u) + \delta)(1 - I(u)) + fS_L(u)] e^{-(t-u)r} du \\
 &\quad + (1 - \alpha) \int_0^{t-\sigma^{-1}} [(\lambda I(u) + \delta)(1 - I(u)) + fS_L(u)] e^{-(t-u)r} du
 \end{aligned}$$

Differentiation yields the following delay differential equation:

$$\begin{aligned}
 \frac{dI}{dt} &= (\lambda I(t) + \delta)(1 - I(t)) + fS_L(t) \\
 &\quad - \alpha e^{-r/\sigma} [(\lambda I(t - \sigma^{-1}) + \delta)(1 - I(t - \sigma^{-1})) + fS_L(t - \sigma^{-1})] \\
 &\quad - r [I(t) - I^{Start}(t)] + \frac{dI^{Start}(t)}{dt}
 \end{aligned}$$

594 A.2 Delay with exponential waiting time: using ordinary differential equations

If effective treatment is applied to a proportion α after an exponentially distributed waiting time with mean σ^{-1} , the function P is of the form

$$P(t) = (1 - \alpha) + \alpha e^{-\sigma t}.$$

If we assume this treatment scheme to apply to those starting being infected, the equation 12 reduces to

$$\begin{aligned} I(t) = & (1 - \alpha)I(0)e^{-rt} + \alpha_{corr}I(0)e^{-(r+\sigma)t} \\ & + (1 - \alpha) \int_0^t [(\lambda I(u) + \delta)(1 - I(u)) + fS_L(u)] e^{r(t-u)} du \\ & + \alpha \int_0^t [(\lambda I(u) + \delta)(1 - I(u)) + fS_L(u)] e^{(\sigma+r)(t-u)} du. \end{aligned}$$

Differentiation yields

$$\begin{aligned} \frac{dI}{dt} = & -r(1 - \alpha)I(0)e^{-rt} - (r + \sigma)\alpha I(0)e^{-(r+\sigma)t} \\ & + (1 - \alpha)[(\lambda I(t) + \delta)(1 - I(t)) + fS_L(t)] - r(1 - \alpha) \int_0^t [(\lambda I(u) + \delta)(1 - I(u)) + fS_L(u)] e^{-r(t-u)} du \\ & + \alpha [(\lambda I(t) + \delta)(1 - I(t)) + fS_L(t)] - (r + \sigma)\alpha \int_0^t [(\lambda I(u) + \delta)(1 - I(u)) + fS_L(u)] e^{-(r+\sigma)(t-u)} du. \end{aligned}$$

We can simplify this by separating those α that get effective treatment from those $1 - \alpha$ that don't. If we consider this separation not at the time the treatment is effective but at the time of infection, this defines two separate classes U for those that don't have access to treatment and T for those that have access to treatment into which α of the newly infected get sorted. Of these, $\frac{\sigma}{r+\sigma}$ actually get effective treatment, after an average waiting time of $\frac{1}{r+\sigma}$, accounting for the possibility to recover before receiving the effective treatment. Then, we have a system of integral equations

$$\begin{aligned} U_L(t) + U_0(t) = & (U_L(0) + U_0(0))e^{-rt} + \int_0^t (1 - \alpha)[(\lambda I(u) + \delta)(1 - I(u)) + fS_L(u)] e^{-r(t-u)} du \\ T_L(t) + T_0(t) = & (T_L(0) + T_0(0))e^{-(r+\sigma)t} + \int_0^t \alpha [(\lambda I(u) + \delta)(1 - I(u)) + fS_L(u)] e^{-(r+\sigma)(t-u)} du \end{aligned}$$

which when differentiated yield

$$\begin{aligned} \frac{d(U_L + U_0)}{dt}(t) = & (1 - \alpha)[(\lambda I(t) + \delta)(1 - I(t)) + fS_L(t)] - r(U_L(t) + U_0(t)) \\ \frac{d(T_L + T_0)}{dt}(t) = & \alpha [(\lambda I(t) + \delta)(1 - I(t)) + fS_L(t)] - (r + \sigma)(T_L(t) + T_0(t)) \end{aligned}$$

595 and therefore to

$$\begin{aligned} \frac{dU_L}{dt} = & (1 - \alpha)(\lambda(U_L + U_0 + T_L + T_0) + \delta)(S_0 + S_L) + (\lambda(U_L + U_0 + T_L + T_0) + \delta)U_0 + (1 - \alpha)fS_L - \gamma_L U_L - rU_L \\ \frac{dU_0}{dt} = & -(\lambda(U_L + U_0 + T_L + T_0) + \delta)U_0 + \gamma_L U_L - rU_0 \\ \frac{dT_L}{dt} = & (1 - \beta)\sigma T_L - (\lambda(U_0 + U_L + T_L + T_0) + \delta)S_L - fS_L - \gamma_L S_L + rU_L + rT_L \\ \frac{dT_0}{dt} = & -(\lambda(U_L + U_0 + T_L + T_0) + \delta)S_0 + \sigma T_L + \sigma T_0 + \gamma_L S_L + rU_0 + rT_0 \\ \frac{dT_L}{dt} = & \alpha(\lambda(U_L + U_0 + T_L + T_0) + \delta)(S_0 + S_L) + \alpha fS_L - \sigma T_L - rT_L - \gamma_L T_L + (\lambda(U_L + U_0 + T_L + T_0) + \delta)T_0 \\ \frac{dT_0}{dt} = & \gamma_L T_L - \sigma T_0 - (\lambda(U_L + U_0 + T_L + T_0) + \delta)T_0 - rT_0 \end{aligned} \tag{13}$$

596 which is equivalent to the model with delayed treatment in the case $\beta = 1$.

597 As a final remark, one can note that taking the limit $\sigma \rightarrow \infty$ we get the initial model with instantantaneous
598 treatment (11), while letting $\sigma = 0$ we get the model (11) without treatment, as is to be expected.

599

600 It is worth noting that the actual probability of getting treated in both scenarios is not α (since some
601 infected will already have recovered by the end of the delay), but $\alpha_{corr_d} = \alpha e^{-r\sigma}$ in the model with with
602 constant delay and $\alpha_{corr} = \alpha \frac{\sigma}{r+\sigma}$ in the model with geometrically distributed delay. These numbers are also
603 the proportions by which the average length of infection is reduced by including treatment.

604

605 These results are not easily generalized to the case where $\beta < 1$, due to the complexity of the integral
606 equations. Nonetheless, the model (13) was extended to the case with imperfect radical cure ($\beta < 1$) leading
607 to model (1) presented in the main text.

608

609 B Back-calculation of the transmission rate in the model with 610 delayed treatment

611 B.1 Model equilibrium

Let T_L^* , T_0^* , U_L^* , U_0^* , S_L^* , S_0^* , and I^* be the equilibrium proportions.

At the equilibrium, we have the equations

$$0 = \frac{dU_L}{dt} = (1 - \alpha)(\lambda I^* + \delta)(1 - I^*) + (1 - \alpha)fS_L^* + (\lambda I^* + \delta)U_0^* - \gamma_L U_L^* - rU_L^* \quad (14)$$

$$0 = \frac{dU_0}{dt} = -(\lambda I^* + \delta)U_0^* + \gamma_L U_L^* - rU_0^* \quad (15)$$

$$0 = \frac{dT_L}{dt} = \alpha(\lambda I^* + \delta)(1 - I^*) + \alpha fS_L^* + (\lambda I^* + \delta)T_0^* - \gamma_L T_L^* - (r + \sigma)T_L^* \quad (16)$$

$$0 = \frac{dT_0}{dt} = -(\lambda I^* + \delta)T_0^* + \gamma_L T_L^* - (r + \sigma)T_0^* \quad (17)$$

$$0 = \frac{dS_L}{dt} = -(\lambda I^* + \delta + f)S_L^* + (1 - \beta)\sigma T_L^* - \gamma_L S_L^* + r(T_L^* + U_L^*) \quad (18)$$

$$0 = \frac{dS_0}{dt} = -(\lambda I^* + \delta)S_0^* + \beta\sigma T_L^* + \sigma T_0^* + \gamma_L S_L^* + r(T_0^* + U_0^*) \quad (19)$$

By adding equations (16) and (17) we obtain the additional equation:

$$0 = \alpha(\lambda I^* + \delta)(1 - I^*) + \alpha fS_L^* - (r + \sigma)(T_L^* + T_0^*)$$

Likewise, by adding equations (14) and (15) we obtain the further equation:

$$0 = (1 - \alpha)(\lambda I^* + \delta)(1 - I^*) + (1 - \alpha)fS_L^* - r(U_0^* + U_L^*).$$

Hence we find the relations

$$T_L^* + T_0^* = \frac{\alpha}{r + \sigma} ((\lambda I^* + \delta)(1 - I^*) + fS_L^*),$$

$$U_L^* + U_0^* = \frac{1 - \alpha}{r} ((\lambda I^* + \delta)(1 - I^*) + fS_L^*),$$

612

which can be combined to get

$$I^* = T_L^* + T_0^* + U_0^* + U_L^* = \frac{r + (1 - \alpha)\sigma}{r(r + \sigma)} ((\lambda I^* + \delta)(1 - I^*) + fS_L^*) \quad (20)$$

and

$$T_L^* + T_0^* = \frac{\alpha r}{r + (1 - \alpha)\sigma} I^*$$

$$U_L^* + U_0^* = \frac{(1 - \alpha)(r + \sigma)}{r + (1 - \alpha)\sigma} I^*$$

613 We define the observed incidence $h := \rho[(\lambda I^* + \delta)(1 - I^*) + fS_L^*]$ as the rate of observed newly arising
 614 blood-stage infections, where ρ is a reporting rate. Starting from equation (20), we can calculate I^* from
 615 observed quantities and model parameters as:

$$I^* = \frac{h(r + (1 - \alpha)\sigma)}{\rho r(r + \sigma)}$$

616 As $r > 0$ is necessary for the denominator to not be zero and is verified in all biologically plausible cases,
 617 we will continue with this assumption throughout the rest of the paper. If on the other hand $h = 0$, we
 618 have $I^* = 0$. Being in the disease-free equilibrium makes it impossible to derive λ . Because of this, we will
 619 also make the further assumption $h > 0$. It is worth noting that in this model, as opposed to that without
 620 treatment delay, $\alpha = 1$ is not ruled out.

621 The proportion p of imported cases is defined such that $ph := \rho\delta(1 - I^*)$ represents the imported cases
 622 and $(1 - p)h = \rho[\lambda I^*(1 - I^*) + fS_L^*]$ the locally acquired cases. Therefore, δ can be derived from observed
 623 quantities and model parameters exactly as in the model without delay:

$$\delta = \frac{ph}{\rho(1 - I^*)} = \frac{phr(r + \sigma)}{\rho r(r + \sigma) - h(r + (1 - \alpha)\sigma)}$$

We then rely on the equilibrium relationships to calculate λ based on observed incidence h and the other model parameters.

We start by solving equation (17) for T_0^* :

$$T_0^* = \frac{\gamma_L}{\lambda I^* + \delta + \gamma_L + r + \sigma} (T_L^* + T_0^*)$$

$$= \frac{\gamma_L}{\lambda I^* + \delta + \gamma_L + r + \sigma} \frac{\alpha r}{r + (1 - \alpha)\sigma} I^*,$$

from which we arrive at the equation

$$T_L^* = \frac{\lambda I^* + \delta + r + \sigma}{\lambda I^* + \delta + \gamma_L + r + \sigma} \frac{\alpha r}{r + (1 - \alpha)\sigma} I^*,$$

(neither of the denominators is zero as we assumed $r > 0$).

Likewise, we solve equation (15) for U_0^* :

$$U_0^* = \frac{\gamma_L}{\lambda I^* + \delta + \gamma_L + r} (U_0^* + U_L^*)$$

$$= \frac{\gamma_L}{\lambda I^* + \delta + \gamma_L + r} \frac{(1 - \alpha)(r + \sigma)}{r + (1 - \alpha)\sigma} I^*,$$

from which we arrive at the equation

$$U_L^* = \frac{\lambda I^* + \delta + r}{\lambda I^* + \delta + \gamma_L + r} \frac{(1 - \alpha)(r + \sigma)}{r + (1 - \alpha)\sigma} I^*,$$

624 (again, neither of the denominators is zero).

625 Solving (18) for S_L^* gives:

$$S_L^* = \frac{rU_L^* + (r + (1 - \beta)\sigma)T_L^*}{\lambda I^* + \delta + \gamma_L + f} \tag{21}$$

626 (the denominator cannot be 0, since $\lambda I^* = \delta = f = 0$ would imply $h = 0$).

Plugging both the equations for T_L^* and U_L^* into (21) yields:

$$\begin{aligned} S_L^* &= \frac{r(1-\alpha)(r+\sigma)(\lambda I^* + \delta + r)(\lambda I^* + \delta + \gamma_L + r + \sigma)I^* + (r + (1-\beta)\sigma)\alpha r(\lambda I^* + \delta + r + \sigma)(\lambda I^* + \delta + \gamma_L + r)I^*}{(\lambda I^* + \delta + \gamma_L + f)(\lambda I^* + \delta + \gamma_L + r)(\lambda I^* + \delta + \gamma_L + r + \sigma)(r + (1-\alpha)\sigma)} \\ &= \frac{(r + (1-\alpha\beta)\sigma)(\lambda I^* + \delta + r)(\lambda I^* + \delta + \gamma_L + r + \sigma) + \alpha(r + (1-\beta)\sigma)\gamma_L\sigma}{(\lambda I^* + \delta + \gamma_L + f)(\lambda I^* + \delta + \gamma_L + r)(\lambda I^* + \delta + \gamma_L + r + \sigma)(r + (1-\alpha)\sigma)} r I^* \end{aligned}$$

We can simplify further by using the identity $\alpha_{corr} = \frac{\sigma}{r+\sigma}$:

$$S_L = \frac{(1 - \alpha_{corr}\beta)(\lambda I^* + \delta + r)(\lambda I^* + \delta + \gamma_L + r + \sigma) + \alpha_{corr}(r + (1 - \beta)\sigma)\gamma_L}{(\lambda I^* + \delta + \gamma_L + f)(\lambda I^* + \delta + \gamma_L + r)(\lambda I^* + \delta + \gamma_L + r + \sigma)(1 - \alpha_{corr})} r I^*.$$

627 B.2 Polynomial equation

628 Now, plugging this into (20) and multiplying by $(\lambda I^* + \delta + \gamma_L + f)(\lambda I^* + \delta + \gamma_L + r)(\lambda I^* + \delta + \gamma_L + r + \sigma)$
629 we obtain:

$$\begin{aligned} 0 &= (\lambda I^* + \delta + \gamma_L + f)(\lambda I^* + \delta + \gamma_L + r)(\lambda I^* + \delta + \gamma_L + r + \sigma) \left((\lambda I^* + \delta)(1 - I^*) - \frac{r(r + \sigma)I^*}{r + (1 - \alpha)\sigma} \right) \\ &\quad + \frac{rI^*}{r + (1 - \alpha)\sigma} f(r + (1 - \alpha\beta)\sigma)(\lambda I^* + \delta + r)(\lambda I^* + \delta + \gamma_L + r + \sigma) + \frac{rI^*}{r + (1 - \alpha)\sigma} f\alpha(r + (1 - \beta)\sigma)\gamma_L\sigma \end{aligned} \tag{22}$$

or, equivalently,

$$\begin{aligned} 0 &= (\lambda I^* + \delta + \gamma_L + f)(\lambda I^* + \delta + \gamma_L + r)(\lambda I^* + \delta + \gamma_L + r + \sigma) \left((\lambda I^* + \delta)(1 - I^*) - \frac{rI^*}{1 - \alpha_{corr}} \right) \\ &\quad + \frac{rI^*}{1 - \alpha_{corr}} f(1 - \alpha_{corr}\beta)(\lambda I^* + \delta + r)(\lambda I^* + \delta + \gamma_L + r + \sigma) + \frac{rI^*}{1 - \alpha_{corr}} f\alpha_{corr}(r + (1 - \beta)\sigma)\gamma_L \end{aligned}$$

630 Rearranging the terms by powers of λ , we get the equation:

$$\begin{aligned} 0 &= \lambda^4 I^{*4} (1 - I^*) \\ &\quad + \lambda^3 I^{*3} \left[(1 - I^*) (4\delta + 3\gamma_L + 2r + f + \sigma) - \frac{rI^*}{1 - \alpha_{corr}} \right] \\ &\quad + \lambda^2 I^{*2} \left[(1 - I^*) ((\delta + \gamma_L + r)(3\delta + 3\gamma_L + r + 2f) + \delta(3\delta + 3\gamma_L + 2r + f) + \sigma(3\delta + 2\gamma_L + r + f)) \right. \\ &\quad \left. - \frac{rI^*}{1 - \alpha_{corr}} (3\delta + 3\gamma_L + 2r + \alpha_{corr}\beta f + \sigma) \right] \\ &\quad + \lambda I^* \left[(1 - I^*) (\delta + \gamma_L + r) [(\delta + \gamma_L + f)(\delta + \gamma_L + r) + \delta(3\delta + 3\gamma_L + r + 2f)] \right. \\ &\quad + (1 - I^*) \sigma [(\delta + \gamma_L + f)(\delta + \gamma_L + r) + \delta(2\delta + 2\gamma_L + r + f)] \\ &\quad - \frac{rI^*}{1 - \alpha_{corr}} [(\delta + \gamma_L + r)(3\delta + 3\gamma_L + r + 2\alpha_{corr}\beta f) + (1 - \alpha_{corr}\beta) f \gamma_L] \\ &\quad \left. - \frac{rI^*}{1 - \alpha_{corr}} \sigma (2\delta + 2\gamma_L + r + \alpha_{corr}\beta f) \right] \\ &\quad + (1 - I^*) \delta (\delta + \gamma_L + r) (\delta + \gamma_L + f) (\delta + \gamma_L + r + \sigma) \\ &\quad - \frac{rI^*}{1 - \alpha_{corr}} [(\delta + \gamma_L + r) [(\delta + \gamma_L + r) (\delta + \gamma_L + \alpha_{corr}\beta f) + (1 - \alpha_{corr}\beta) \gamma_L f] - \alpha_{corr} f \gamma_L r] \\ &\quad - \frac{rI^*}{1 - \alpha_{corr}} \sigma [(\delta + \gamma_L + r) (\delta + \gamma_L + \alpha_{corr}\beta f) + (1 - \alpha_{corr}) f \gamma_L] \end{aligned}$$

631 As long the assumptions $r > 0$ and $h > 0$ are met, multiplication by the denominator of S_L^* is an equivalent
 632 transformation, so any non-negative root of this polynomial is a solution of the system of equilibrium equa-
 633 tions.

634 It can be noted that the equation in the setting without delay can be derived from this one by dividing by
 635 σ and taking the limit $\sigma \rightarrow \infty$ (corresponding to a delay decreasing to 0).

636 We get the same qualitative result as in the setting without delayed treatment:

Theorem B.1. *If $h > 0$ and $r > 0$, the function*

$$P(\lambda) = (\lambda I^* + \delta + \gamma_L + f)(\lambda I^* + \delta + \gamma_L + r)(\lambda I^* + \delta + \gamma_L + r + \sigma) \left((\lambda I^* + \delta)(1 - I^*) - \frac{rI^*}{r + (1 - \alpha)\sigma}(r + \sigma) \right) \\ + \frac{rI^*}{r + (1 - \alpha)\sigma} f(r + (1 - \alpha)\sigma)(\lambda I^* + \delta + r + \sigma)(\lambda I^* + \delta + \gamma_L + r) - \frac{rI^*}{r + (1 - \alpha)\sigma} (1 - \alpha)f(r + \sigma)\gamma_L\sigma$$

637 *has at most one positive real root.*

638 *It has two non-negative real roots (i.e. one of them is 0) only if $\alpha\beta\sigma = \gamma_L = \delta = 0$ (corresponding to an*
 639 *equilibrium of relapses and recoveries without liver-stage clearance).*

640 Thanks to this result, it is possible to solve the polynomial equation numerically in order to back-calculate
 641 the parameter λ required to reproduce the reported data, assuming that the model is at equilibrium.

Proof of Theorem B.1. Before beginning the proof, we point to the fact that $h > 0$ and $r > 0$ imply $0 < I^* < 1$.

We start with the case $f = 0$ like in the model without delay ?

From the shape of equation 22 one can easily see that the four roots in that case are

$$-\frac{\gamma_L + \delta + r + \sigma}{I^*}, -\frac{\gamma_L + \delta + r}{I^*}, -\frac{\gamma_L + \delta}{I^*} \quad \text{and} \quad \frac{r(r + \sigma)}{r + (1 - \alpha)\sigma} \frac{1}{1 - I^*} - \frac{\delta}{I^*},$$

ordered from smallest to largest. Only the last two of them may be non-negative, and the first of these only in the case $\gamma_L = \delta = 0$, and in that case, from $\lambda = \delta = f = 0$ it follows $h = 0$, contradicting our assumption, so this is no solution.

Now we turn to the case $f > 0$.

To make the dependence of P on f visible, let us denote it P_f . Then,

$$P_f(\lambda) = P_0(\lambda) + fQ(\lambda)$$

642 with

$$Q(\lambda) = (\lambda I^* + \delta + \gamma_L + r)(\lambda I^* + \delta + \gamma_L + r + \sigma) \left((\lambda I^* + \delta)(1 - I^*) - \frac{r(r + \sigma)}{r + (1 - \alpha)\sigma} I^* \right) \\ + \frac{r(r + (1 - \alpha)\sigma)}{r + (1 - \alpha)\sigma} I^* (\lambda I^* + \delta + r + \sigma)(\lambda I^* + \delta + \gamma_L + r) - \frac{r(r + \sigma)}{r + (1 - \alpha)\sigma} I^* (1 - \alpha)\gamma_L\sigma \\ = \underbrace{(\lambda I^* + \delta + \gamma_L + r)(\lambda I^* + \delta + \gamma_L + r + \sigma) \left((\lambda I^* + \delta)(1 - I^*) - \frac{\alpha\beta r\sigma}{r + (1 - \alpha)\sigma} I^* \right)}_{R(\lambda)} \\ + \underbrace{\left(-\frac{r(r + (1 - \alpha)\sigma)}{r + (1 - \alpha)\sigma} I^* \gamma_L (\lambda I^* + \delta + \gamma_L + r) \right) - \frac{r(r + \sigma)}{r + (1 - \alpha)\sigma} I^* (1 - \alpha)\gamma_L\sigma}_{S(\lambda)}$$

643 It is easily seen that $P_0 + fR$ is a polynomial of degree 4 with positive leading coefficient and two roots at
 644 $\lambda_1 := -\frac{\delta + \gamma_L + r + \sigma}{I^*}$ and $\lambda_2 := -\frac{\delta + \gamma_L + r}{I^*}$.

645 Let us now first consider the case $\gamma_L > 0$. In that case we also see that

$$\underbrace{P_0\left(-\frac{\delta}{I^*}\right)}_{<0} + f \underbrace{R\left(-\frac{\delta}{I^*}\right)}_{\leq 0} < 0. \quad (23)$$

646 As $\lim_{\lambda \rightarrow \infty} P_0(\lambda) + fR(\lambda) = \infty$, from the intermediate value theorem it follows that $P_0 + fR$ has a root λ_4
 647 to the right of $-\frac{\delta}{I^*}$. Since every simple root is accompanied with a sign change, the last root λ_3 has to be
 648 to the left of $-\frac{\delta}{I^*}$. In particular, λ_1, λ_2 and λ_3 are all negative.

649 We will now prove that by adding $fS(\lambda) = -f \frac{r(r+(1-\alpha)\sigma)}{r+(1-\alpha)\sigma} I^* \gamma_L (\lambda I^* + \delta + \gamma_L + r) - f \frac{r(r+\sigma)}{r+(1-\alpha)\sigma} I^* (1-\alpha)$, we
 650 will not get a non-negative root:

651 It is easily seen that $fS(\lambda) < 0$ for all $\lambda \geq 0$, so

$$P_f(\lambda) = P_0(\lambda) + fR(\lambda) + fS(\lambda) < 0 \quad \text{for } \lambda \in [0, \lambda_4], \quad (24)$$

652 implying that there cannot be a root in that interval.

653 On the other hand, it is a known fact that the inflection points of a polynomial of degree 4 lie between the
 654 smallest and the largest root. This implies that $P_0 + fR$ is strictly convex in the interval $]\lambda_4, \infty[$. Since
 655 $P_f = P_0 + fR + fS$ has the same second derivative, it is also strictly convex in that interval. This, combined
 656 with the fact that $P_f(\lambda_4) = fS(\lambda_4) < 0$, implies that there is only one root of P_f in that interval. This
 657 finishes the proof in the case $\gamma_L > 0$.

658 Now we turn to the case $\gamma_L = 0$. Then, $P_f = P_0 + fR$.

659 We again know the two roots $-\frac{\delta+r+\sigma}{I^*}, -\frac{\delta+r}{I^*}$ and we see that

$$P_f\left(-\frac{\delta}{I^*}\right) = \underbrace{P_0\left(-\frac{\delta}{I^*}\right)}_{=0} + fR\left(-\frac{\delta}{I^*}\right) = - \underbrace{fr(r+\sigma)}_{\neq 0} \frac{\alpha\beta r\sigma}{r+(1-\alpha)\sigma} I^*. \quad (25)$$

660 If this term is 0 (which is the case if and only if $\alpha\beta\sigma = 0$), we know that $-\frac{\delta}{I^*}$ is also a root of P_f . This
 661 root is only non-negative if $\delta = 0$, which is the case of endless relapses and recoveries without liver-stage
 662 clearance.

663 Otherwise, the term must be negative. Then again, since every simple root is accompanied with a sign
 664 change, we know that there must be exactly one root to the right of $-\frac{\delta}{I^*}$. \square

C Back-calculation of the transmission rate in the models with RCD

C.1 Model with RCD and without delayed treatment

In this section exclusively, we use the notations $I = I_L + I_0$ and $I^* = I_L^* + I_0^*$.

In the absence of delays in treatment, the model with RCD is described by the following equations:

$$\begin{aligned}
 \frac{dI_L}{dt} &= (1 - \alpha)(\lambda I + \delta)(1 - I) + (1 - \alpha)fS_L + (\lambda I + \delta)I_0 - \gamma_L I_L - rI_L \\
 &\quad - \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta I_L \\
 \frac{dI_0}{dt} &= -(\lambda I + \delta)I_0 + \gamma_L I_L - rI_0 - \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta I_0 \\
 \frac{dS_L}{dt} &= \alpha(1 - \beta)(\lambda I + \delta)S_0 - (1 - \alpha(1 - \beta))(\lambda I + \delta + f)S_L - \gamma_L S_L + rI_L \\
 &\quad + (1 - \beta)\min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta I_L \\
 \frac{dS_0}{dt} &= -(1 - \alpha\beta)(\lambda I + \delta)S_0 + \alpha\beta(\lambda I + \delta + f)S_L + \gamma_L S_L + rI_0 \\
 &\quad + \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta(\beta I_L + I_0)
 \end{aligned} \tag{26}$$

In the case of $\iota_{max}\nu\tau\eta = 0$, this reduces to the model without treatment delays in Champagne et al. [2022].

If there is no importation ($\delta = 0$) and τ is fixed (or at least bounded), all of the 'RCD terms' are of the order $O(I^2)$ for $I \rightarrow 0$, so the R_C value is equal to the R_C without any RCD, similarly to the model with treatment delays (4).

C.1.1 Model equilibrium

At equilibrium, adding the equations for I_L and I_0 in (26), we get

$$0 = \frac{dI}{dt} = (1 - \alpha)(\lambda I^* + \delta)(1 - I^*) + (1 - \alpha)fS_L^* - rI^* - \iota^*\nu\tau\eta I^* \tag{27}$$

where $\iota^* = \min(\iota_{max}, \rho(\lambda I^* + \delta)(1 - I^*) + \rho fS_L^*)$.

Following the same steps as in the model without RCD [Champagne et al., 2022], we find

$$\begin{aligned}
 I_L^* &= \frac{\lambda I^* + \delta + r + \iota^*\nu\tau\eta}{\lambda I^* + \delta + \gamma_L + r + \iota^*\nu\tau\eta} I^* \\
 S_L^* &= \frac{(r + (1 - \beta)\iota^*\nu\tau\eta)I_L^* + \alpha(1 - \beta)(\lambda I^* + \delta)(1 - I^*)}{\lambda I^* + \delta + \gamma_L + (1 - \alpha(1 - \beta))f}
 \end{aligned}$$

C.1.2 Polynomial equation

Solving these equations for λ gives the following polynomial equation:

$$\begin{aligned}
 0 &= P^{RCD}(\lambda) \\
 &= (\lambda I^* + \delta + \gamma_L + f)(\lambda I^* + \delta + \gamma_L + r + \iota^*\nu\tau\eta) \left((\lambda I^* + \delta)(1 - I^*) - \frac{r + \iota^*\nu\tau\eta}{1 - \alpha} I^* \right) \\
 &\quad + (r + (1 - \beta)\iota^*\nu\tau\eta)f(\lambda I^* + \delta + r + \iota^*\nu\tau\eta)I^* + \alpha(1 - \beta)\frac{r + \iota^*\nu\tau\eta}{1 - \alpha}f(\lambda I^* + \delta + \gamma_L + r + \iota^*\nu\tau\eta)I^* \\
 &= P_{r+\iota^*\nu\tau\eta}^{no\ RCD}(\lambda) - \beta f \iota^* \nu \tau \eta (\lambda I^* + \delta + r + \iota^* \nu \tau \eta) I^*
 \end{aligned}$$

where $P_{r+\iota^*\nu\tau\eta}^{no\ RCD}$ is the corresponding polynomial in the setting without RCD [Champagne et al., 2022], but with r replaced by $r + \iota^*\nu\tau\eta$. This equation can be used to back-calculate the transmission rate λ from

683 observable quantities. The same formulae as in section 2.2.1 can be used to calculate ι^* , I^* and δ , using
 684 $I = I_L + I_0$ and α instead of α_{corr} .

685

The singularity of the solution can be shown similarly to the case without RCD [Champagne et al., 2022].

$$P_f^{RCD}(\lambda) = P_0^{RCD}(\lambda) + fQ^{RCD}(\lambda)$$

with

$$P_0^{RCD}(\lambda) = (\lambda I^* + \delta + \gamma_L)(\lambda I^* + \delta + \gamma_L + r + \nu\tau\eta) \left((\lambda I^* + \delta)(1 - I^*) - \frac{r + \nu\tau\eta}{1 - \alpha} I^* \right)$$

and

$$Q^{RCD}(\lambda) = (\lambda I^* + \delta + \gamma_L + r + \nu\tau\eta) \left((\lambda I^* + \delta)(1 - I^*) - \alpha\beta \frac{r + \nu\tau\eta}{1 - \alpha} I^* - \beta\nu\tau\eta I^* \right) - (r + (1 - \beta)\nu\tau\eta)\gamma_L I^*.$$

686 As expected, at equilibrium, for $\beta = 0$, adding the RCD term is equivalent to changing r to $r + \iota^*\nu\tau\eta$ (but
 687 note that ι^* depends on the equilibrium states of the model I^* and S_L^*). As β approaches 1, the difference
 688 between the two models increases.

689

690 C.2 Back-calculation of the transmission rate in the model with delayed treat- 691 ment and RCD (no referral)

692 In this section, additional results on the model (4) are provided.

693 C.2.1 Relation to other models

694 First, the model represented by (4) is related to other models in the following way:

- 695 • In the limit of $\sigma \rightarrow \infty$, the model is equivalent to the non-delay RCD model (26).
- 696 • There are some more equivalences if ι is fixed instead of capped:
 - 697 – If $\beta = 0$ and $\sigma > \nu\tau\eta$, the model is equivalent to the model with delayed treatment and no RCD
 698 (1) with r replaced with $r + \nu\tau\eta$ and σ replaced with $\sigma - \nu\tau\eta$.
 - 699 – If $\beta = 0$ and $\sigma < \nu\tau\eta$, the model is instead equivalent to the model with delayed treatment and
 700 no RCD (1) with r replaced with $r + \sigma$, σ replaced with $\nu\tau\eta - \sigma$, α replaced with $1 - \alpha$ and T_L
 701 and T_0 swapped with U_L and U_0 , respectively.
 - 702 – If $\beta = 0$ and $\sigma = \nu\tau\eta$, the model is equivalent to the non-delay vivax model [Champagne et al.,
 703 2022] with r replaced with $r + \sigma$, α set to 0 and T_L and T_0 added to U_L and U_0 , respectively.
 - 704 – If $\sigma = 0$, the model is equivalent to the model with delayed treatment and no RCD (1) with σ
 705 replaced with $\nu\tau\eta$, α replaced with $1 - \alpha$ and T_L and T_0 swapped with U_L and U_0 , respectively.

706 Such correspondences are used in the R package to test the correctness of the model implementation.

707 C.2.2 Model equilibrium

708 At equilibrium, adding the equations for U_L and U_0 in (4), we get

$$0 = (1 - \alpha)(\lambda I^* + \delta)(1 - I^*) + (1 - \alpha)fS_L^* - (r + \nu\tau\eta)(U_L^* + U_0^*) \quad (28)$$

709 and similarly by adding the equations for T_L and T_0 in (4),

$$0 = \alpha(\lambda I^* + \delta)(1 - I^*) + \alpha fS_L^* - (r + \sigma)(T_L^* + T_0^*) \quad (29)$$

710 Finally, by adding both of these, we find

$$(\lambda I^* + \delta)(1 - I^*) + fS_L^* = (r + \sigma)(T_0^* + T_L^*) + (r + \nu\tau\eta)(U_L^* + U_0^*) \quad (30)$$

which can be inserted into either (28) or (29) to get

$$(1 - \alpha)(r + \sigma)(T_0^* + T_L^*) = \alpha(r + \omega\tau\eta)(I_0^* + I_L^*) \quad (31)$$

$$U_L^* + U_0^* = \frac{(1 - \alpha)(r + \sigma)}{r + (1 - \alpha)\sigma + \alpha\omega\tau\eta} I^* \quad (32)$$

$$T_L^* + T_0^* = \frac{\alpha(r + \omega\tau\eta)}{r + (1 - \alpha)\sigma + \alpha\omega\tau\eta} I^* \quad (33)$$

From the equation for U_0 in (4), we obtain

$$\begin{aligned} U_0^* &= \frac{\gamma_L(U_L^* + U_0^*)}{\lambda I^* + \delta + \gamma_L + r + \omega\tau\eta} \\ &= \frac{\gamma_L(1 - \alpha)(r + \sigma)}{\lambda I^* + \delta + \gamma_L + r + \omega\tau\eta} \frac{I^*}{r + (1 - \alpha)\sigma + \alpha\omega\tau\eta} \\ U_L^* &= \frac{(\lambda I^* + \delta + r + \omega\tau\eta)(1 - \alpha)(r + \sigma)}{\lambda I^* + \delta + \gamma_L + r + \omega\tau\eta} \frac{I^*}{r + (1 - \alpha)\sigma + \alpha\omega\tau\eta}. \end{aligned}$$

From the equation for T_0 in (4), we obtain

$$\begin{aligned} T_0^* &= \frac{\gamma_L(T_0^* + T_L^*)}{\lambda I^* + \delta + \gamma_L + r + \sigma} \\ &= \frac{\gamma_L\alpha(r + \omega\tau\eta)}{\lambda I^* + \delta + \gamma_L + r + \sigma} \frac{I^*}{r + (1 - \alpha)\sigma + \alpha\omega\tau\eta} \\ T_L^* &= \frac{(\lambda I^* + \delta + r + \sigma)\alpha(r + \omega\tau\eta)}{\lambda I^* + \delta + \gamma_L + r + \sigma} \frac{I^*}{r + (1 - \alpha)\sigma + \alpha\omega\tau\eta}. \end{aligned}$$

Inserting these results into the equation for S_L in (4), yields

$$S_L^* = \frac{(r + (1 - \beta)\omega\tau\eta)I_L^* + (r + (1 - \beta)\sigma)T_L^*}{\lambda I^* + \delta + \gamma_L + f}$$

711 C.2.3 Polynomial equation

Plugging this into (30) yields

$$\begin{aligned} 0 &= P(\lambda) \\ &= (\lambda I^* + \delta + \gamma_L + f)(\lambda I^* + \delta + \gamma_L + r + \omega\tau\eta)(\lambda I^* + \delta + \gamma_L + r + \sigma) \left((1 - I^*)(\lambda I^* + \delta) - \frac{(r + \omega\tau\eta)(r + \sigma)I^*}{r + (1 - \alpha)\sigma + \alpha\omega\tau\eta} \right) \\ &\quad + \frac{f(r^2 + (1 - \alpha\beta)r\sigma + (1 - (1 - \alpha)\beta)r\omega\tau\eta + (1 - \beta)\sigma\omega\tau\eta)(\lambda I^* + \delta + r + \sigma)(\lambda I^* + \delta + \gamma_L + r + \omega\tau\eta)I^*}{r + (1 - \alpha)\sigma + \alpha\omega\tau\eta} \\ &\quad + \frac{f(1 - \alpha)(r + (1 - \beta)\omega\tau\eta)(r + \sigma)\gamma_L(\omega\tau\eta - \sigma)I^*}{r + (1 - \alpha_{corr})\sigma + \alpha\omega\tau\eta} \\ &= P_{\tilde{r}=r+\omega\tau\eta, \tilde{\sigma}=\sigma-\omega\tau\eta}^{no\ RCD}(\lambda) \\ &\quad - \beta\omega\tau\eta f(\lambda I^* + \delta + \tilde{r})(\lambda I^* + \delta + \gamma_L + \tilde{r} + \tilde{\sigma})I^* \\ &\quad - \beta\omega\tau\eta f \frac{\alpha\tilde{r}\tilde{\sigma}\gamma_L I^*}{\tilde{r} + (1 - \alpha)\tilde{\sigma}} \end{aligned}$$

712 This equation can be used to back-calculate the transmission rate λ from observable quantities.

713 C.3 Model with delayed treatment and RCD, including referral to health facil- 714 ity for cases detected via RCD

715 The model with delay in treatment and referral of reactively detected cases can be formulated as follows
716 (noting $I = U_L + U_0 + T_L + T_0$):

$$\begin{aligned}
 \frac{dU_L}{dt} &= (1 - \alpha)(\lambda I + \delta)(1 - I) + (1 - \alpha)fS_L + (\lambda I + \delta)U_0 - \gamma_L U_L - rU_L \\
 &\quad - \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_L \\
 \frac{dU_0}{dt} &= -(\lambda I + \delta)U_0 + \gamma_L U_L - rU_0 - \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_0 \\
 \frac{dT_L}{dt} &= \alpha(\lambda I + \delta)(1 - I) + \alpha fS_L + (\lambda I + \delta)T_0 - \gamma_L T_L - (r + \sigma)T_L \\
 &\quad + \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_L \\
 \frac{dT_0}{dt} &= -(\lambda I + \delta)T_0 + \gamma_L T_L - (r + \sigma)T_0 \\
 &\quad + \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_0 \\
 \frac{dS_L}{dt} &= -(\lambda I^* + \delta + f)S_L + (1 - \beta)\sigma T_L - \gamma_L S_L + r(T_L + U_L) \\
 \frac{dS_0}{dt} &= -(\lambda I + \delta)S_0 + \beta\sigma T_L + \sigma T_0 + \gamma_L S_L + r(T_0 + U_0)
 \end{aligned} \tag{34}$$

717 Similarly to model (4), if there is no importation ($\delta = 0$) and τ is fixed (or at least bounded), all of the
718 'RCD terms' are of the order $O(I^2)$ for $I \rightarrow 0$, so the R_C values are the same and equal to the R_C without
719 any RCD.

720

721 C.3.1 Relation to other models

722 Again, we can make some connections to other models:

- 723 • If $\nu\tau\eta = 0$, this model is the same as the model with delayed treatment and no RCD (1).
- 724 • In the limit of $\sigma \rightarrow \infty$, the model is equivalent to the non-delay RCD vivax model (26).
- 725 • If $\sigma = 0$, the model is equivalent to the non-delay vivax model without either treatment or RCD
726 [Champagne et al., 2022] with T_L and T_0 added to U_L and U_0 , respectively.

727 C.3.2 Model equilibrium

728 Adding the equations for U_L and U_0 in (34), we get

$$0 = (1 - \alpha)(\lambda I^* + \delta)(1 - I^*) + (1 - \alpha_{corr})fS_L^* - r(I_L^* + I_0^*) - \nu\tau\eta(I_L^* + I_0^*), \tag{35}$$

729 and similarly by adding the equations for T_L and T_0 in (34),

$$0 = \alpha(\lambda I^* + \delta)(1 - I^*) + \alpha_{corr}fS_L^* - (r + \sigma)(T_L^* + T_0^*) + \nu\tau\eta(I_L^* + I_0^*). \tag{36}$$

730 Finally, by adding both of these, we find

$$(\lambda I^* + \delta)(1 - I^*) + fS_L^* = (r + \sigma)(T_0^* + T_L^*) + r(I_0^* + I_L^*), \tag{37}$$

which can be inserted into either (35) or (36) to get

$$(1 - \alpha)(r + \sigma)(T_0^* + T_L^*) = (\alpha r + \nu\tau\eta)(I_0^* + I_L^*) \tag{38}$$

$$I_L^* + I_0^* = \frac{(1 - \alpha)(r + \sigma)}{r + (1 - \alpha)\sigma + \nu\tau\eta} I^* \tag{39}$$

$$T_L^* + T_0^* = \frac{\alpha r + \nu\tau\eta}{r + (1 - \alpha)\sigma + \nu\tau\eta} I^* \tag{40}$$

From the equation for U_0 in (34), we obtain

$$I_0^* = \frac{\gamma_L(I_0^* + I_L^*)}{\lambda I^* + \delta + \gamma_L + r + \omega\tau\eta}$$

$$U_L^* = (U_0^* + U_L^*) - U_0^*$$

From the equation for T_0 in (34), we obtain

$$T_0^* = \frac{\gamma_L(T_0^* + T_L^*) + \omega\tau\eta I_0^*}{\lambda I^* + \delta + \gamma_L + r + \sigma}$$

$$T_L^* = (T_0^* + T_L^*) - T_0^*$$

Inserting these results into the equation for S_L in (34) yields

$$S_L^* = \frac{rI_L^* + (r + (1 - \beta)\sigma)T_L^*}{\lambda I^* + \delta + \gamma_L + f}$$

$$= \frac{(r(r + (1 - \alpha\beta)\sigma) + \omega\tau\eta(r + (1 - \beta)\sigma))(\lambda I^* + \delta + r + \sigma)(\lambda I^* + \delta + \gamma_L + r + \omega\tau\eta)I^*}{(\lambda I^* + \delta + \gamma_L + f)(\lambda I^* + \delta + \gamma_L + r + \omega\tau\eta)(\lambda I^* + \delta + \gamma_L + r + \sigma)(r + (1 - \alpha)\sigma + \omega\tau\eta)}$$

$$- \frac{(1 - \alpha)(r + (1 - \beta)\omega\tau\eta)(r + \sigma)\gamma_L\sigma I^*}{(\lambda I^* + \delta + \gamma_L + f)(\lambda I^* + \delta + \gamma_L + r + \omega\tau\eta)(\lambda I^* + \delta + \gamma_L + r + \sigma)(r + (1 - \alpha)\sigma + \omega\tau\eta)}.$$

731 C.3.3 Polynomial equation

732 Plugging this into (37) yields

$$0 = P(\lambda)$$

$$= (\lambda I^* + \delta + \gamma_L + f)(\lambda I^* + \delta + \gamma_L + r + \omega\tau\eta)(\lambda I^* + \delta + \gamma_L + r + \sigma) \left((1 - I^*)(\lambda I^* + \delta) - \frac{(r + \omega\tau\eta)(r + \sigma)I^*}{r + (1 - \alpha)\sigma + \omega\tau\eta} \right)$$

$$+ \frac{I^*}{r + (1 - \alpha)\sigma + \omega\tau\eta} f(r(r + (1 - \alpha_{corr}\beta)\sigma) + \omega\tau\eta(r + (1 - \beta)\sigma))(\lambda I^* + \delta + r + \sigma)(\lambda I^* + \delta + \gamma_L + r + \omega\tau\eta)$$

$$- \frac{I^*}{r + (1 - \alpha)\sigma + \omega\tau\eta} f(1 - \alpha)(r + (1 - \beta)\omega\tau\eta)(r + \sigma)\gamma_L\sigma$$

733 This equation can be used to back-calculate the transmission rate λ from observable quantities. The
734 same formulae as in section 2.2.1 can be used to calculate i^* , I^* and δ .

735

736 D Description of the other models including MDA

737 D.1 No treatment delays, no RCD

738 The model is represented by the following ODE system:

$$\frac{dI_L}{dt} = (1 - \alpha)(\lambda I + \delta)(S_L + S_0) + (\lambda I + \delta)I_0 + (1 - \alpha)fS_L - \gamma_L I_L - rI_L$$

$$\frac{dI_0}{dt} = -(\lambda I + \delta)I_0 + \gamma_L I_L - rI_0$$

$$\frac{dS_L}{dt} = -(1 - \alpha(1 - \beta))(\lambda I + \delta)S_L + \alpha(1 - \beta)(\lambda I + \delta)S_0 - (1 - \alpha(1 - \beta))fS_L - \gamma_L S_L + rI_L$$

$$\frac{dS_0}{dt} = -(1 - \alpha\beta)(\lambda I + \delta)S_0 + \alpha\beta(\lambda I + \delta)S_L + \alpha\beta fS_L + \gamma_L S_L + rI_0$$

$$\frac{dP_L}{dt} = -\gamma_L P_L$$

$$\frac{dP_0}{dt} = \gamma_L P_L.$$
(41)

739 starting with $P_L(0) = P_0(0) = 0$.
 740 At time t_{MDA} , we take the new values

$$\begin{aligned}
 I_L(t_{MDA}) &= (1 - c_{MDA})I_L(t_{MDA}^-) \\
 I_0(t_{MDA}) &= (1 - c_{MDA})I_0(t_{MDA}^-) \\
 S_L(t_{MDA}) &= (1 - c_{MDA})S_L(t_{MDA}^-) \\
 S_0(t_{MDA}) &= (1 - c_{MDA})S_0(t_{MDA}^-) \\
 P_L(t_{MDA}) &= c_{MDA}(1 - \beta_{MDA})I_L(t_{MDA}^-) + c_{MDA}(1 - \beta_{MDA})S_L(t_{MDA}^-) \\
 P_0(t_{MDA}) &= c_{MDA}\beta_{MDA}I_L(t_{MDA}^-) + c_{MDA}\beta_{MDA}S_L(t_{MDA}^-) + c_{MDA}I_0(t_{MDA}^-) + c_{MDA}S_0(t_{MDA}^-)
 \end{aligned} \tag{42}$$

741 and at time $t_{MDA} + p_{MDA}$, we take the values

$$\begin{aligned}
 I_L(t_{MDA} + p_{MDA}) &= I_L((t_{MDA} + p_{MDA})^-) \\
 I_0(t_{MDA} + p_{MDA}) &= I_0((t_{MDA} + p_{MDA})^-) \\
 S_L(t_{MDA} + p_{MDA}) &= S_L((t_{MDA} + p_{MDA})^-) + P_L((t_{MDA} + p_{MDA})^-) \\
 S_0(t_{MDA} + p_{MDA}) &= S_0((t_{MDA} + p_{MDA})^-) + P_0((t_{MDA} + p_{MDA})^-) \\
 P_L(t_{MDA} + p_{MDA}) &= 0 \\
 P_0(t_{MDA} + p_{MDA}) &= 0
 \end{aligned} \tag{43}$$

742 and continue the simulation from there.

743 D.2 No treatment delays, with RCD

744 The model is represented by the following ODE system:

$$\begin{aligned}
 \frac{dI_L}{dt} &= (1 - \alpha)(\lambda I + \delta)(1 - I) + (1 - \alpha)fS_L + (\lambda I + \delta)I_0 - \gamma_L I_L - rI_L \\
 &\quad - \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta I_L \\
 \frac{dI_0}{dt} &= -(\lambda I + \delta)I_0 + \gamma_L I_L - rI_0 - \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta I_0 \\
 \frac{dS_L}{dt} &= \alpha(1 - \beta)(\lambda I + \delta)S_0 - (1 - \alpha(1 - \beta))(\lambda I + \delta + f)S_L - \gamma_L S_L + rI_L \\
 &\quad + (1 - \beta)\min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta I_L \\
 \frac{dS_0}{dt} &= -(1 - \alpha\beta)(\lambda I + \delta)S_0 + \alpha\beta(\lambda I + \delta + f)S_L + \gamma_L S_L + rI_0 \\
 &\quad + \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta(\beta I_L + I_0) \\
 \frac{dP_L}{dt} &= -\gamma_L P_L \\
 \frac{dP_0}{dt} &= \gamma_L P_L,
 \end{aligned} \tag{44}$$

745 starting with $P_L(0) = P_0(0) = 0$.
 746 At time t_{MDA} , we take the new values

$$\begin{aligned}
 I_L(t_{MDA}) &= (1 - c_{MDA})I_L(t_{MDA}^-) \\
 I_0(t_{MDA}) &= (1 - c_{MDA})I_0(t_{MDA}^-) \\
 S_L(t_{MDA}) &= (1 - c_{MDA})S_L(t_{MDA}^-) \\
 S_0(t_{MDA}) &= (1 - c_{MDA})S_0(t_{MDA}^-) \\
 P_L(t_{MDA}) &= c_{MDA}(1 - \beta_{MDA})I_L(t_{MDA}^-) + c_{MDA}(1 - \beta_{MDA})S_L(t_{MDA}^-) \\
 P_0(t_{MDA}) &= c_{MDA}\beta_{MDA}I_L(t_{MDA}^-) + c_{MDA}\beta_{MDA}S_L(t_{MDA}^-) + c_{MDA}I_0(t_{MDA}^-) + c_{MDA}S_0(t_{MDA}^-)
 \end{aligned} \tag{45}$$

747 and at time $t_{MDA} + p_{MDA}$, we take the values

$$\begin{aligned}
 I_L(t_{MDA} + p_{MDA}) &= I_L((t_{MDA} + p_{MDA})^-) \\
 I_0(t_{MDA} + p_{MDA}) &= I_0((t_{MDA} + p_{MDA})^-) \\
 S_L(t_{MDA} + p_{MDA}) &= S_L((t_{MDA} + p_{MDA})^-) + P_L((t_{MDA} + p_{MDA})^-) \\
 S_0(t_{MDA} + p_{MDA}) &= S_0((t_{MDA} + p_{MDA})^-) + P_0((t_{MDA} + p_{MDA})^-) \\
 P_L(t_{MDA} + p_{MDA}) &= 0 \\
 P_0(t_{MDA} + p_{MDA}) &= 0.
 \end{aligned} \tag{46}$$

748 D.3 RCD without referral to health facilities

749 The model is represented by the following ODE system:

$$\begin{aligned}
 \frac{dU_L}{dt} &= (1 - \alpha)(\lambda I + \delta)(1 - I) + (1 - \alpha)fS_L + (\lambda I + \delta)U_0 - \gamma_L U_L - rU_L \\
 &\quad - \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_L \\
 \frac{dU_0}{dt} &= -(\lambda I + \delta)U_0 + \gamma_L U_L - rU_0 - \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_0 \\
 \frac{dS_L}{dt} &= -(\lambda I + \delta + f)S_L + (1 - \beta)\sigma T_L - \gamma_L S_L + r(T_L + U_L) \\
 &\quad + (1 - \beta)\min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_L \\
 \frac{dT_L}{dt} &= \alpha(\lambda I + \delta)(1 - I) + \alpha fS_L + (\lambda I + \delta)T_0 - \gamma_L T_L - (r + \sigma)T_L \\
 \frac{dT_0}{dt} &= -(\lambda I + \delta)T_0 + \gamma_L T_L - (r + \sigma)T_0 \\
 \frac{dS_0}{dt} &= -(\lambda I + \delta)S_0 + \beta\sigma T_L + \sigma T_0 + \gamma_L S_L + r(T_0 + U_0) \\
 &\quad + \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta(\beta U_L + U_0) \\
 \frac{dP_L}{dt} &= -\gamma_L P_L \\
 \frac{dP_0}{dt} &= \gamma_L P_L,
 \end{aligned} \tag{47}$$

750 starting with $P_L(0) = P_0(0) = 0$.

751 At time t_{MDA} , we take the new values

$$\begin{aligned}
 U_L(t_{MDA}) &= (1 - c_{MDA})U_L(t_{MDA}^-) \\
 U_0(t_{MDA}) &= (1 - c_{MDA})U_0(t_{MDA}^-) \\
 T_L(t_{MDA}) &= (1 - c_{MDA})T_L(t_{MDA}^-) \\
 T_0(t_{MDA}) &= (1 - c_{MDA})T_0(t_{MDA}^-) \\
 S_L(t_{MDA}) &= (1 - c_{MDA})S_L(t_{MDA}^-) \\
 S_0(t_{MDA}) &= (1 - c_{MDA})S_0(t_{MDA}^-) \\
 P_L(t_{MDA}) &= c_{MDA}(1 - \beta_{MDA})(T_L(t_{MDA}^-) + U_L(t_{MDA}^-) + S_L(t_{MDA}^-)) \\
 P_0(t_{MDA}) &= c_{MDA}\beta_{MDA}(T_L(t_{MDA}^-) + U_L(t_{MDA}^-) + S_L(t_{MDA}^-)) + c_{MDA}(T_0(t_{MDA}^-) + U_0(t_{MDA}^-) + S_0(t_{MDA}^-)).
 \end{aligned} \tag{48}$$

752 At last, at time $t_{MDA} + p_{MDA}$, we take the new values

$$\begin{aligned}
 U_L(t_{MDA} + p_{MDA}) &= U_L((t_{MDA} + p_{MDA})^-) \\
 U_0(t_{MDA} + p_{MDA}) &= U_0((t_{MDA} + p_{MDA})^-) \\
 T_L(t_{MDA} + p_{MDA}) &= T_L((t_{MDA} + p_{MDA})^-) \\
 T_0(t_{MDA} + p_{MDA}) &= T_0((t_{MDA} + p_{MDA})^-) \\
 S_L(t_{MDA} + p_{MDA}) &= S_L((t_{MDA} + p_{MDA})^-) + P_L((t_{MDA} + p_{MDA})^-) \\
 S_0(t_{MDA} + p_{MDA}) &= S_0((t_{MDA} + p_{MDA})^-) + P_0((t_{MDA} + p_{MDA})^-) \\
 P_L(t_{MDA} + p_{MDA}) &= 0 \\
 P_0(t_{MDA} + p_{MDA}) &= 0.
 \end{aligned} \tag{49}$$

753 D.4 RCD with referral to health facilities

754 The model is represented by the following ODE system:

$$\begin{aligned}
 \frac{dU_L}{dt} &= (1 - \alpha)(\lambda I + \delta)(1 - I) + (1 - \alpha)fS_L + (\lambda I + \delta)U_0 - \gamma_L U_L - rU_L \\
 &\quad - \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_L \\
 \frac{dU_0}{dt} &= -(\lambda I + \delta)U_0 + \gamma_L U_L - rU_0 - \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_0 \\
 \frac{dT_L}{dt} &= \alpha(\lambda I + \delta)(1 - I) + \alpha fS_L + (\lambda I + \delta)T_0 - \gamma_L T_L - (r + \sigma)T_L \\
 &\quad + \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_L \\
 \frac{dT_0}{dt} &= -(\lambda I + \delta)T_0 + \gamma_L T_L - (r + \sigma)T_0 + \min(\iota_{max}, \rho(\lambda I + \delta)(1 - I) + \rho fS_L)\nu\tau\eta U_0 \\
 \frac{dS_L}{dt} &= -(\lambda I + \delta + f)S_L + (1 - \beta)\sigma T_L - \gamma_L S_L + r(T_L + U_L) \\
 \frac{dS_0}{dt} &= -(\lambda I + \delta)S_0 + \beta\sigma T_L + \sigma T_0 + \gamma_L S_L + r(T_0 + U_0) \\
 \frac{dP_L}{dt} &= -\gamma_L P_L \\
 \frac{dP_0}{dt} &= \gamma_L P_L,
 \end{aligned} \tag{50}$$

755 starting with $P_L(0) = P_0(0) = 0$.

756 At time t_{MDA} , we take the new values

$$\begin{aligned}
 U_L(t_{MDA}) &= (1 - c_{MDA})U_L(t_{MDA}^-) \\
 U_0(t_{MDA}) &= (1 - c_{MDA})U_0(t_{MDA}^-) \\
 T_L(t_{MDA}) &= (1 - c_{MDA})T_L(t_{MDA}^-) \\
 T_0(t_{MDA}) &= (1 - c_{MDA})T_0(t_{MDA}^-) \\
 S_L(t_{MDA}) &= (1 - c_{MDA})S_L(t_{MDA}^-) \\
 S_0(t_{MDA}) &= (1 - c_{MDA})S_0(t_{MDA}^-) \\
 P_L(t_{MDA}) &= c_{MDA}(1 - \beta_{MDA})(T_L(t_{MDA}^-) + U_L(t_{MDA}^-) + S_L(t_{MDA}^-)) \\
 P_0(t_{MDA}) &= c_{MDA}\beta_{MDA}(T_L(t_{MDA}^-) + U_L(t_{MDA}^-) + S_L(t_{MDA}^-)) + c_{MDA}(T_0(t_{MDA}^-) + U_0(t_{MDA}^-) + S_0(t_{MDA}^-)).
 \end{aligned} \tag{51}$$

757 At last, at time $t_{MDA} + p_{MDA}$, we take the new values

$$\begin{aligned}U_L(t_{MDA} + p_{MDA}) &= U_L((t_{MDA} + p_{MDA})^-) \\U_0(t_{MDA} + p_{MDA}) &= U_0((t_{MDA} + p_{MDA})^-) \\T_L(t_{MDA} + p_{MDA}) &= T_L((t_{MDA} + p_{MDA})^-) \\T_0(t_{MDA} + p_{MDA}) &= T_0((t_{MDA} + p_{MDA})^-) \\S_L(t_{MDA} + p_{MDA}) &= S_L((t_{MDA} + p_{MDA})^-) + P_L((t_{MDA} + p_{MDA})^-) \\S_0(t_{MDA} + p_{MDA}) &= S_0((t_{MDA} + p_{MDA})^-) + P_0((t_{MDA} + p_{MDA})^-) \\P_L(t_{MDA} + p_{MDA}) &= 0 \\P_0(t_{MDA} + p_{MDA}) &= 0.\end{aligned}\tag{52}$$